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INTRODUCTION  
 Asthma and chronic obstructive pulmonary disease (COPD) are the two most prevalent 
chronic airway diseases.  Much of the morbidity, mortality and health care costs of the diseases 
are associated with exacerbations. Exacerbations are acute episodes that punctuated the natural 
history of the disease characterized by increased symptoms and airflow obstruction determining 
quality of life impairment and with possible effect on long term history of the disease. Thus, the 
prevention and the treatment of exacerbations are major tasks in the management of both asthma 
and COPD.  However currently available treatment are only partially effective in reducing the 
incidence of such events.  
 Over the last decade evidence has emerged implicating virus respiratory tract infections as 
a major cause of exacerbations both in asthma and in COPD.  In particular, rhinovirus (i.e. the 
etiologic cause of the common cold) is the most frequently identify virus during exacerbations of 
both asthma and COPD.  
 The comprehension of the inflammatory and immunological mechanisms that pave the 
way for exacerbation following respiratory tract infection in asthmatic and COPD patients will 
give the opportunity to highlight novel potential targets for pharmacological intervention. The 
recent development of in vivo experimental models of rhinovirus induced asthma and COPD 
exacerbations represents the unique tool to evaluate pathogenetic mechanisms and novel 
pharmacological pathways for treating and preventing COPD and asthma exacerbations.  
 The aim of the present thesis is to review the data available on inflammatory and 
immunological mechanisms of virus induced exacerbations of asthma and COPD and to present 
the results of the studies conducted by the Candidate to enlighten the emerging field of virus 
induced asthma and COPD exacerbations.   
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ROLE OF VIRUS INFECTION IN ASTHMA EXACERBATIONS   
 
Asthma and exacerbations: definition 
 Asthma is a chronic inflammatory disease of the airways characterized by recurrent acute 
or subacute episodes of progressively worsening shortness of breath, cough, wheezing, and chest 
tightness or some combination of these symptoms (1). These events are named exacerbations. In 
addition exacerbations are characterized by worsening in lung function below the patient’s usual 
values.  Acute exacerbations are one of the most important (if not the most important) events in 
the natural history of asthma. They result in excess medication use, emergency department visits, 
hospitalisation, and even death. Additionally, asthma exacerbations reduce quality of life and lead 
to time off work and school with the associated emotional and financial stress this entails. From a 
societal perspective, exacerbations are the main driver of asthma-related costs, accounting for 
almost 50% of total costs (2).   
 
Epidemiology of asthma exacerbation 
 In line with the increasing prevalence of asthma there has been an increasing burden of 
disease associated with acute exacerbations. Much of the morbidity and virtually all of the deaths 
associated with asthma are due to acute exacerbations and even among patients receiving optimal 
asthma therapy 20% will experience a severe exacerbation (3). In the USA there are an estimated 
2 million visits to Emergency Departments and 500,000 hospital admissions per year due to 
asthma (1). In the UK over 17 million working days are lost every year due to asthma, with the 
total annual cost to the UK economy estimated at over £1 billion.  The annual average treatment 
costs per patient are > 3.5 times higher for asthmatics who experience an exacerbation (4).    
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 For many years general opinion has been that respiratory virus infections were the cause 
of the common cold, and were able to produce serious pulmonary complications only in infants, 
the elderly and immunocompromised subjects. It is now widely recognised that respiratory viral 
infections of the airways are also the most important causes of asthma exacerbations both in 
children and adults (5). The health costs of asthma exacerbations are enormous in terms of days 
lost from work or school, general practitioner consultations, hospital admissions and mortality. 
Despite optimised therapy for stable asthma with inhaled glucocorticoids and long-acting β2 
agonists asthma exacerbations continue to occur suggesting that the pathogenesis of asthma 
exacerbations and of stable asthma are likely to be different (6). The cellular and molecular 
mechanisms underlying these events have been studied and partially elucidated in the last few 
years but more studies are needed to fully understand the mechanisms of asthma exacerbations so 
that new more effective therapies can be developed. 
 
Role of respiratory viruses infection in asthma exacerbations: clinical evidence 
i) Prevalence of respiratory viruses infection in asthma exacerbations. 
 Initial studies designed to establish the relationship between virus infection and asthma 
exacerbations utilised virus isolation in cell culture from upper airway samples or detection of 
increasing titres of virus-specific serum antibodies to recognise respiratory virus infections. Since 
the techniques were relatively insensitive the frequency of viral detection was low. The 
development of molecular virology techniques, in particular of reverse transcription-polymerase 
chain reaction (RT-PCR) assays for the identification of respiratory viruses in biological samples, 
has provided a more sensitive tool to evaluate the role of respiratory viruses in the natural history 
of asthma. Clinical studies performed using RT-PCR suggest that the proportion of virus-induced 
asthma exacerbations is likely be around 80 to 85%  in school-aged children (7)  and  60-75% in 
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adults of the total number of exacerbations, rhinovirus being the virus type most frequently 
identified (8).  
 
ii) Severity of virus-induced asthma exacerbations. 
 Respiratory viral infections not only contribute substantially to asthma morbidity in mild-
moderate asthma, but they also appear to be associated with more severe exacerbations. In fact, 
upper respiratory viral infections are strongly associated in time with hospital admissions for 
asthma both in adults and in children (9-11). A recent study showed that asthma exacerbations in 
which a virus was detected were associated with a more compromised lower forced expiratory 
volume in one second (FEV1), higher hospital admission rate and longer hospital stay. In this 
study, sputum lactate dehydrogenase (LDH) level, a marker of cell lysis and virus-induced 
bronchial epithelium damage, was significantly higher in the patients with viral infection and was 
the major predictor of length of hospital stay suggesting evidence for causation and not just 
association of viral infection in severe asthma exacerbations (8). These data also suggest that the 
degree of virus-induced epithelial damage to the lower airways is the major determinant of the 
severity of the exacerbation. 
Winter peaks in asthma mortality have been observed in adults over 45 years of age, suggesting 
that respiratory virus infections, which are more frequent in winter, may also precipitate asthma 
deaths in these age groups (12-14).  
 
iii) Synergism between viral infection and atopy 
 There are both clinical and experimental evidence indicating that respiratory viruses can 
act synergistically with other factors such as allergic sensitisation to exacerbate asthma. 
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 The risk of wheezing in children is increased by the concomitant presence of virus 
infection and exposure to an allergen the child is sensitised to. Indeed, a large majority of 
wheezing episodes during childhood can be linked to infection with rhinovirus, and  they are 
most likely to occur in those who have rhinovirus infection together with evidence of atopy or 
sputum eosinophilia (15). In a study of adult asthmatics with  asthma exacerbations, the risk of 
hospital admission was strongly associated with the combination of allergic sensitisation, 
exposure to allergens the patient was sensitised to and concurrent viral infection (16).   
 Also human experimental infection indicates a synergistic effect between virus infection 
and allergen exposure. Indeed, several studies have demonstrated that rhinovirus enhances 
allergen-induced inflammatory responses in the lower airways, including histamine release, 
eosinophil recruitment and the induction of late-phase airway response (17, 18).  
 In rhinitic patients, experimental rhinovirus infection performed after nasal allergen 
challenge increase significantly the levels of both eosinophil peroxidase (EPO) and 
myeloperoxidase (MPO), in nasal lavage fluid suggesting a synergistic effect between allergen 
and rhinovirus in the activation of eosinophils and neutrophil granulocytes (19). The same 
authors in a previous study, showed that in patients with seasonal allergic rhinitis, experimental 
infection performed 4 days before allergen nasal challenge caused a significant increase of 
interleukin (IL)-8, eosinophil cationic protein (ECP) and α2-macroglobulin levels in the nasal 
lavage fluid (20). Finally, atopic adult with mild asthma and elevated levels of total serum 
immunoglobulin E (IgE) show greater lower respiratory tract symptoms during experimental 
rhinovirus infection compared with asthmatic patients with lower levels of IgE (21).  
 These synergistic effects have also been described in animal models. After respiratory 
syncytial virus (RSV) infection in mice sensitised to a specific allergen there is an increase in 
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airway hyperresponsiveness and of the number of Th2 lymphocytes in the animals previously 
exposed to the allergen compared with infected mice but not allergen challenged (22). 
 However, not all the clinical studies have reached the same conclusions:  for instance a 
study performed on adult atopic asthmatic failed to show any additive or synergistic effect 
between allergen challenge and virus infection (23) and one study has even shown a protective 
effect of allergen exposure on virus infection (24).  
 Several causes could be responsible for the differences observed in different clinical and 
experimental settings. One possible explanation relates to the anti-inflammatory and antiviral 
immune response that could be evoked in some conditions by chronic allergen exposure. Indeed, 
chronic allergen exposure could induce the production in the airways of anti-inflammatory 
cytokines, such as IL-10, and/or antiviral mediators, such as interferon-γ (IFN)-γ, with 
consequent down regulation of airway inflammation and/or of the viral infectivity. Another 
possible mechanism is associated to the increase in the levels of exhaled nitric oxide (NO) 
occurring during asthmatic exacerbations (25). As discussed in details below, NO may play an 
important role in host defences against viruses. Also, differences in the timing and doses of 
allergens involved in different clinical/experimental setting could account for the differences 
observed in the outcomes of these studies.  
 Further studies are required to elucidate the complexity of the interactions between 
allergen exposure and respiratory virus infection on the modulation of airway inflammation 
during asthmatic exacerbations (26).  
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Role of respiratory viruses infection in asthma exacerbations: experimental models 
 Much of our current knowledge regarding virus-asthma interactions comes from 
experimental models. Obtaining samples from the lower airways for studying the mechanisms of 
asthma exacerbations is difficult for both logistical and ethical reasons. Experimental rhinovirus 
infection in human volunteers has long been used to study the pathogenesis of the common cold 
and this technique has also been used in subjects with mild asthma.  The results of these studies 
will be reviewed here (Figure 1).  
 
i) Experimental infection: clinical and functional consequences 
 Experimental rhinovirus infection of asthmatic patients can cause both cold and asthma 
symptoms (21, 27, 28). Several studies suggest that experimental rhinovirus infection can 
increase airway responsiveness. Increased airway responsiveness usually begins early after RV 
viral infection both in asthmatic and in nonasthmatic atopic subjects (29, 30). Rhinovirus-induced 
increases in airway responsiveness are greater in subjects with lower baseline pulmonary function 
(31) and in asthmatics with more severe cold symptoms (32).  By detailed monitoring it has been 
possible to detect reductions in both peak expiratory flow (PEF) (32) and FEV1 in a fraction of 
atopic asthmatic patients in the acute phase of experimental rhinovirus infection (28). However, it 
should be underlined that not every asthmatic patient experimentally infected with rhinovirus 
develop cold and/or asthma symptoms and/or a significant decrease of their PEF/FEV1 (33). The 
reasons for these differences are unknown and may relate to amount of rhinovirus inoculated, 
experimental conditions and intersubject variability in the immune/inflammatory response to 
rhinovirus. 
 
iii) Cellular and molecular mechanisms of respiratory virus infections and asthma exacerbations 
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 Despite mounting clinical evidence for a major role of respiratory viral infections in the 
pathogenesis of asthma exacerbations, the mechanisms of respiratory virus-induced airway 
inflammation during asthma exacerbations are relatively uncertain. 
 
a) Pro-inflammatory and anti-inflammatory mediators released from epithelial cells 
 Respiratory viruses enter and replicate within epithelial cells lining the lower airways.  
The extent of epithelial cell destruction that they can cause varies according to the type of virus. 
Influenza virus typically causes extensive epithelial necrosis whereas rhinovirus causes little or 
only patchy epithelial damage (34). Death/damage of epithelial cells results in both an increase in 
epithelial permeability and increased penetration of irritants and allergens and exposure of the 
extensive network of sensory nerve fibres. These effects may contribute to the increased airway 
hyperresponsiveness induced by respiratory virus infection.  
 There is increasing evidence that the epithelium of the lower airway does not simply act 
as a physical barrier but has important regulatory roles on the immune/inflammatory response. 
Bronchial epithelial cells may act as antigen-presenting cells particularly during memory 
responses to respiratory viral infections. They express major histocompatibility complex (MHC) I 
and the costimulatory molecules CD80 (B7.1) and CD86 (B7.2), whose expression is upregulated 
in vitro by RV (35).  
 Bronchial epithelial cells also contribute to the inflammatory response that follows virus 
infection through the production of cytokines and chemokines. In vitro infection of these cells 
with rhinovirus induces the secretion of IL-1β, IL-6, IL-8, IL-11, tumour necrosis factor alpha 
(TNF-α), CCL-5 (RANTES), CCL11 (eotaxin-1), CCL24 (eotaxin-2), and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (36). 
These cytokines have profound effects on inflammatory cells involved in asthma exacerbations.  
  
10 
 
 The function of IL-8 as a chemotactic factor for neutrophils and primed eosinophils 
indicates that it may play an important role in triggering the inflammation that leads to 
exacerbations of asthma. IL-8 has been detected in increased amounts in both nasal and sputum 
samples obtained during virus infections, and its levels correlated with induction of airway 
hyperresponsiveness (37) and neutrophilic bronchial inflammation (38).  
 Likewise, the pro-inflammatory cytokine IL-6 is induced by rhinovirus infection (39) and 
IL-6 is increased in the sputum of rhinovirus infected asthmatic subjects (40). Another cytokine 
which may be important in the pathogenesis of virus-induced asthma exacerbations is IL-11. 
IL-11 is secreted in very large amount in vitro and may directly increase airway responsiveness 
(41). Several respiratory viruses including RSV, parainfluenza viruses and rhinovirus strongly 
stimulate its production by lung fibroblasts. IL-11 is increased in nasal aspirates from children 
with upper respiratory infection were its levels are correlated with clinically detectable wheezing 
(42).  Finally, also the eosinophil chemoattractant chemokines CCL-5 and CCL-3 are increased 
during upper respiratory viral infections associated to asthma exacerbations (43).  
 
b) Neurogenic inflammation 
 Another mechanisms that can contribute to the development of asthma symptoms, airflow 
obstruction and airway hyperresponsiveness during acute respiratory viral illness are represented 
by the effects of virus infection on the neural networks of the airways. 
 Both animal and in vitro studies suggest that viral infections could stimulate sensory 
nerves, reflex parasympathetic bronchoconstriction and/or interfering with the function of 
nonadrenergic, noncholinergic (NANC) nerves, which produce bronchodilator mediators such as 
nitric oxide (NO), vasoactive intestinal peptide (VIP) and bronchoconstrictor mediators such as 
tachykinins (substance P and neurokinins) (44).  
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Virus-mediated damage to the epithelial layer can expose the dense subepithelial network of 
unmyelinated afferent sensory fibers, which may increase stimulation of sensory nerves by 
inhaled particles or pro-inflammatory mediators. Sensory nerves can directly release 
neuropeptides, such a tachykinins, that induce contraction of smooth muscle cells, or can trigger 
reflex bronchoconstriction by activating parasympathetic nerves. This reflex causes release of 
acetylcholine (ACh) and contraction of airway smooth muscle cells via stimulation of muscarinic 
M3 receptors. Normally, ACh inhibits its release trough the activation of muscarinic M2 
receptors on the presynapse of the postganglionic parasympathetic (cholinergic) nerves (auto-
inhibitory feedback). In animal models, respiratory viruses, directly and through the release of 
inflammatory mediators, such as major basic protein (MBP), can decrease the expression and/or 
the function of M2 ACh receptors and block this auto-inhibitory feedback, thus enhancing ACh 
release from cholinergic nerves and potentiating reflex parasympathetic bronchoconstriction (44). 
To date, little information is available on the role in humans of neurogenic inflammation in the 
pathogenesis of virus-induced asthma exacerbations. Clinical studies using the dual tachykinin 
NK1/NK2 antagonist DNK333 have shown that this compound inhibits neurokinin A-induced 
bronchoconstriction in patients with stable asthma (45). Clinical trial testing the efficacy of this 
drug in asthma exacerbations are expected. 
 
c) Adhesion molecules 
 Adhesion molecules are glycoproteins involved in inflammatory cell recruitment at sites 
of inflammation. One such molecule is ICAM-1 (CD54) that is expressed on the surface of 
epithelial and endothelial cells and is the natural ligand of the β2 integrin CD11a [lymphocyte 
function antigen 1 (LFA-1)] that is expressed on all leucocytes (46). ICAM-1 may play a 
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particular role as a pathogenetic link between virus infections and asthma exacerbations. ICAM-1 
is the major receptor for rhinovirus binding to human cells.  Approximately 90% of rhinovirus 
serotypes bind to and enter cells using cell surface ICAM-1. Rhinovirus infection of airway 
epithelial cells upregulates expression of ICAM-1 both in vivo and in vitro (47). Through this 
mechanism rhinoviruses are able to increase the expression of its own receptor on the epithelial 
surface, and this event can potentate viral attachment and entry in the host cell.  
 ICAM-1 has been proposed as a marker of persistent inflammation in allergic diseases 
(48). Indeed, in patients with atopic diseases (such as allergic conjunctivitis, allergic rhinitis 
and/or asthma) after spontaneous or experimental exposure to allergen there is an increased 
expression of ICAM-1 on the surface of the conjunctival and/or airway epithelial cells (49) that 
can promote the recruitment and the infiltration of eosinophils, neutrophils and lymphocytes at 
the sites of allergic inflammation. Th2 cytokines, such as IL-4, IL-5 and IL-13 induce in vitro 
increased ICAM-1 expression in bronchial epithelial cells (50). Bianco et al showed that IFN-γ in 
combination with each Th2-associated cytokine only slightly reduces, but does not override, the 
Th2-induced level of ICAM-1 expression on both uninfected and rhinovirus-infected airway 
epithelial cells (51). These data suggest that the effects of Th2-associated cytokines on ICAM-1 
expression and on the recovery of rhinovirus are dominant over the effects of the Th1-associated 
cytokines such as IFN-γ. Since the airway mucosa in atopic asthma is predominantly infiltrated 
by Th2 lymphocytes, these results could partially explain both the increased susceptibility to 
human rhinovirus infection in asthmatic patients (52) and the associated exacerbation of asthma. 
Therefore allergic inflammation, by enhancing the ICAM-1 expression on airway epithelial cells 
may facilitate rhinovirus infection in atopic subjects. Conversely, rhinovirus infection by 
increasing the expression of its own receptor may potentially facilitate both epithelial infections 
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and leukocyte infiltration, which could contribute to the inflammatory cascade that leads to 
exacerbations.  
 A similar pathogenetic role could be referred to another adhesion molecule, vascular 
adhesion molecule-1 (VCAM-1; CD106). At variance with ICAM-1, VCAM-1 selectively 
recruits, among granulocytes, only eosinophils, since neutrophils do not possess the ligand for 
VCAM-1. VCAM-1 is present on the surface of the activated endothelial and epithelial cells and 
its expression is increased in airway mucosa by RV infection and allergen (53). This event could 
favour the recruitment of eosinophils into the airway mucosa and contribute to the development 
of the bronchial eosinophilia observed after experimental RV infection in human volunteers (27, 
47).  
 
d) Nitric oxide 
 Exhaled nitric oxide (NO) is increased during asthma exacerbations both in children and 
adults. Increased levels of exhaled NO are found in nonasthmatic volunteers following natural 
colds (54) as well as in asthmatic patients after experimental rhinovirus infection (55). In the 
latter study an inverse association between the NO increase and worsening of airway 
hyperresponsiveness was demonstrated arguing in favour of a protective role for this molecule.  
Increased NO production by infected epithelial cells of the lower airway may play an important 
role in lung defences against rhinoviruses (55-58). 
 Indeed, in vitro studies of rhinovirus-infected human bronchial epithelial cells have shown 
that NO can inhibit virus replication as well as rhinovirus-induced production of the pro-
inflammatory cytokines IL-6, IL-8, GM-CSF (58).  
Figure 
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 The effects of rhinovirus infection on transcription factor activation have been particularly 
studied in the last few years. Activation of intracellular signalling pathways induced by 
rhinovirus in epithelial cells may be dependent on surface receptor binding (ICAM-1) or by 
intracellular products during viral replication such as double-stranded RNA (dsRNA). It has been 
shown that dsRNA can activate components of several signalling pathways including protein 
kinase R (PKR), NF-κB and p38 mitogen-activated protein kinase (MAPK). It is reasonable to 
hypothesise that this occurs through the binding of TLR3, a member of the toll-like receptors 
(TLR) that recognize molecular patters associated with microbial pathogens and induce 
antimicrobial immune response (60).  However, to date no studies have investigated the role of 
these molecules in rhinovirus infection. 
 Virus induced activation of NF-κB  leads to an increased expression of cytokines [IL-1, 
IL-6, granulocyte colony-stimulating factor (G-CSF), and GM-CSF], CXC chemokines (IL-8) 
and ICAM-1 (47, 61) whereas expression of VCAM-1 seems mediated by activation of NF-κB 
and GATA proteins (53).  
 It has been recently suggested that early activation of p38 MAPK pathway  by rhinovirus 
infection, which induces the activation of many transcription factors, could a key event in the 
regulation of rhinovirus-induced cytokine transcription, and may provide a new target for 
inhibition of rhinovirus-induced asthma exacerbations (62).  
 While a cooperative interaction between NF-kB and AP1 occurs in RSV induced IL-8 
production (63), an oxidant mediated activation of interferon regulatory factor (IRF) is required 
for RSV induced RANTES production (64). 
 Oxidants could represent a key intracellular mediator of virus-induced cellular activation.  
Interestingly, oxidative stress can induce activation of nuclear factor κB (NF-κB) and activator 
protein-1 (AP-1), two pivotal regulators of the inflammatory processes (65). Rhinovirus infection 
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induces increased production of superoxide anion in bronchial epithelial cells and this event is a 
crucial step for the activation of NF-κB and the following production of pro-inflammatory 
cytokines, chemokines and adhesion molecules (66). Reducing agents inhibit both rhinovirus-
induced oxidant generation and inflammatory mediator production and release (66). These data 
suggest that the inhibition of oxidative stress may be a potential therapeutic target for treatment 
of virus-induced asthma exacerbations. 
 
Antiviral immunity in asthmatic patients 
 Recent studies indicate that individuals with asthma are more susceptible to naturally 
occurring rhinovirus infection than normal individuals in that lower respiratory tract symptoms 
and changes in peak expiratory flow were both more severe and of longer duration in the 
asthmatic subjects than in the normal subjects (52). However, the reasons for this increased 
susceptibility in individuals with asthma have to date been largely unknown, but an emerging 
hypothesis supported by in vitro and in vivo experimental viral models is that asthmatic patients 
have a deficient innate and acquired antiviral defence against respiratory virus infections.  
 
i) Decreased IFN-ß-production and apoptosis in asthmatic epithelial cells  
 A novel mechanism for increased susceptibility to rhinovirus infection in asthmatic 
subjects has been recently descibed. Asthmatic bronchial epithelial cells were found to have a 
defect in innate immune responses to rhinovirus infection, with profoundly impaired production 
of IFN-β and apoptosis in response to rhinovirus infection, resulting in greatly increased virus 
replication (67). In contrast normal bronchial epithelial cells rapidly produced IFN-β and 
underwent apoptosis, rendering them almost completely resistant to rhinovirus replication. 
Impaired responses  in asthmatic cells were specifically restricted to innate immunity as 
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measured as IFN-β production and apoptosis while the production of inflammatory mediators 
(IL-6 and RANTES) was not affected (67). Impaired innate immune responses were observed in 
primary bronchial epithelial cells from both steroid naïve and steroid treated asthmatic patients 
(67), and in the presence of dexamethsone indicating that the defects in antiviral immunity were 
not a result of steroid treatment, and that steroids have no effects on apoptotic responses and on 
IFN-β production in bronchial epithelial cells after rhinovirus infection in accordance with the 
clinical observation of relative ineffectiveness of steroids in virus induced asthma exacerbations 
(68). Finally, exposure of bronchial epithelial cells from asthmatics to exogenous IFN-β  restored 
innate immune responses and limited virus replication to levels observed in normals (67). Thus 
signalling pathways downstream of the type I interferon receptor that lead to activation of 
programmed cell death and interferon production are intact. This has important implications for 
therapy, indicating that pharmacologic replacement/augmentation of IFN-β to promote innate 
immune responses could be proposed as a novel approach to prevent and treat virus induced 
asthma exacerbations  
 
ii) Decreased type 1 and increased type 2 NK cell responses in asthma 
 An interesting field of investigation in the innate immune responses to viral infection is 
represented by the antiviral actions exerted by NK cells. There are some data in the literature 
suggesting a role of NK2 cells in the pathogenesis of asthma. Indeed, it has been shown that in 
blood the percentage of IFN-γ-producing NK1 cells is much lower and the percentage of IL-4-
producing NK2 cells is much higher in asthmatic patients as compared to healthy individuals 
(69). Therefore it may be proposed that, in an airway environment rich in type 2 cytokines, NK1 
cell functions and effective antiviral innate immunity might be impaired. If this is the case, then a 
key component of the early immune response would be deficient and viral clearance would be 
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impaired. In addition, if NK2 function is favoured by the asthmatic microenvironment, 
production of type 2 cytokines by NK cells in response to virus infection might be one 
mechanism for amplification of type 2 and impaired of type 1 T cell responses.  However there 
are no studies of NK cell function in the airway in asthma or in virus-induced asthma. 
 
iii) Decreased type 1 T cell antiviral responses in asthma 
 In addition to innate immune responses, acquired immune responses are also important in 
contributing to antiviral immunity. Efficient T cell responses to virus infection are thought to be 
predominantly type 1. It has been suggested that in the lower airways of allergic asthmatics with 
a pre-existing Th2-type allergic inflammation microenvironment, the T cell responses to viral 
infection may be skewed towards inappropriate and potentially harmful type 2 responses. Indeed, 
in a murine model of asthma in transgenic mice expressing virus (lymphocytic choriomeningitis 
virus – LCMV)-specific CD8+ T cells, the induction of a Th2 immune response to ovalbumin was 
able to switch the virus-specific CD8+ T cell response to IL-5 production leading to accumulation 
of eosinophils in the lung (70). By contrast, the virus peptide-specific CD8+ T cell-induced 
responses in non- or sham-immunized transgenic mice resulted in an accumulation of 
neutrophils, without any detectable eosinophil recruitment. Moreover virus peptide-specific lung 
CD8+ T cells from OVA-immunized mice produced IL-5 and reduced levels of IFN-γ whereas 
CD8+ T cells from sham-immunized mice secreted large amounts of IFN-γ and no detectable IL-
5 (70). This data indicates that a Th2 environment in the lung can switch virus-specific CD8+ T 
cell responses to IL-5 production leading to impaired secretion of IFN-γ and delayed clearance of 
the virus from the lung. 
 In vitro human data indicate that exposure of PBMCs to rhinovirus results in an up-
regulation of IFN-γ, and IL-12 (type 1 cytokines produced by T cells and monocytes 
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respectively) production in both normal and atopic asthmatic subjects; however PBMCs from 
asthmatic subjects produced significantly lower levels of IFN-γ and IL-12, demonstrating a 
deficient type 1 cytokine production (71) IL-4 (type 2 cytokine produced by T cells) production 
in PBMC was induced by rhinovirus only in the atopic asthmatic group (71).  
 There is also evidence in vivo that imbalances in type 1/type 2 immune responses 
influence the outcome of rhinovirus infection. Gern et al. showed an inverse relationship between 
the ratio of IFN-γ/IL-5 mRNA in sputum and cold symptoms and time to virus clearance from 
sputum in asthmatics and atopics experimentally infected with rhinovirus, indicating that a 
stronger type 1 immune response is associated with less severe symptoms and faster viral 
clearance (36). Moreover it has been shown that the higher is the in vitro Th1 response to 
rhinovirus infection in PBMCs, measured as IFN-γ production or IFN-γ/IL-5 ratio, the lower is  
the bronchial hyperresponsiveness and the higher is the % predicted FEV1 in stable asthmatic 
patients (72). These data suggest that an impaired Th1 antiviral immune response not only is a 
characteristic of asthmatic patients but it might indirectly reflect the severity of the disease. 
 Taken together these studies suggest that an increased levels of type 2 cytokines in 
asthmatic subjects are likely to be associated with deficient type 1 responses and that this may 
also play a role in the increased susceptibility of asthmatic patients to viral infections. Studies on 
airway T cell responses to rhinovirus infections in asthmatic and normal subjects will be required 
to confirm whether this is indeed the case. 
 A defective Th1 immune response has been implicated in the pathogenesis and severity of 
RSV bronchiolitis both in animal models and in humans. Mice with type 2 cytokine responses 
after RSV infection develop enhanced disease with pulmonary hemorrhage and eosinophilia, 
whereas those with type 1 responses have reduced immunopathology and enhanced viral 
clearance (73). Children with a deficient Th1 and a relative increased Th2 immune response in 
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Conclusions 
 Epidemiological data indicate that respiratory virus infections are the most important 
causes of asthma exacerbations, rhinoviruses being the most frequently identified virus type. 
Experimental infection of normal and asthmatic volunteers indicate that respiratory viruses can 
induce many of the features typical of asthma exacerbations, however until now no major 
differences in the airway responses to viral infection have been observed between asthmatic and 
normal subjects. Viral infections increase the production in the lower airways of several pro-
inflammatory molecules (including cytokines, chemokines and adhesion molecules). Respiratory 
virus-induced activation of neurogenic inflammation is also an emerging field of investigation.  
 Collectively, molecular biology data suggest a critical role for several transcription 
factors, including NF-κB and AP-1, in the production of pro-inflammatory mediators following 
viral infection. Few studies have been conducted on the molecular mechanisms underlying the 
pro-inflammatory responses induced by respiratory viruses in human airways.  
 Results coming from in vitro and in vivo studies indicate that a deficient immune response 
to viral infection, both in the innate immune response and in the adaptive immune response, 
occurs in asthmatic patients (36, 67, 71). The mechanisms of this impaired antiviral immune 
response are unknown. In particular it is unknown whether this is a genetically induced 
impairment or/and whether it is due to the pre-existing asthmatic airway Th2 immune response 
able to inhibit the naturally occurring Th1 immune response that follows viral infection. 
Interestingly a recent in vitro study indicates that the asthmatic defective immune response to 
rhinovirus  in bronchial epithelial cells can be restored by provision of exogenous IFN-β restoring 
innate immune responses and limiting virus replication to levels observed in normals (67). 
Further studies are needed to deeply evaluate the complex immunological events that follow viral 
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infection in asthmatic patients in order find out possible mechanisms responsible for the 
increased susceptibility of asthmatic patients to viral infection. 
 The relative importance of each cell, mediator, signalling pathway and transcription factor 
will hopefully be clarified in the next few years. Such knowledge will enable development of 
compounds able to block a specific cell/mediator signalling molecule and/or transcription factor 
and permit testing of new possible targets for the treatment of virus-induced asthma 
exacerbations. 
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ROLE OF VIRUS INFECTIONS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 
EXACERBATIONS 
 
COPD and exacerbations: definition 
 Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease 
with some significant extrapulmonary effects that may contribute to the severity in individual 
patients. Its pulmonary component is characterized by airflow limitation that is not fully 
reversible. The airflow limitation is usually progressive and associated with an abnormal 
inflammatory response of the lung to noxious particles or gases (1).  
 The natural history of the disease is punctuated by recurrent exacerbations, i.e. acute 
events characterized by a change in the patient’s baseline dyspnea, cough, or sputum beyond day-
to-day variability and sufficient to warrant a change in management. Acute exacerbations are a 
common occurrence for many COPD patients. In addition to the morbidity and mortality 
attributable to the acute episode, exacerbations contribute to loss of lung function and impaired 
health status in COPD (1-3). Prevention or amelioration of exacerbations has become a major 
therapeutic outcome for the evaluation of existing and new therapeutic agents for COPD. There is 
no universally accepted definition of an exacerbation of COPD. The typical symptoms of 
exacerbation include breathlessness, cough, increased sputum production and purulence, wheeze 
and chest tightness. Although usually clinicians have little difficulty in diagnosing an 
exacerbation of COPD, establishing a universally accepted definition for epidemiological or 
interventional studies has proved difficult. The two most widely used approaches have been to 
use symptom-based definitions or event-based definitions, but both of these approaches have 
potential drawbacks. Symptom-based definitions rely on the patient reporting a worsening of 
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dyspnea and increases in sputum volume or purulence, but there are no symptoms or 
physiological measurements that are diagnostic of exacerbation. Symptoms are the primary 
concern of the patient and it is generally a worsening of symptoms that prompts patients to seek 
medical advice. However such a definition relies on a subjective assessment by the patient and 
there is great variability in the threshold at which patients perceive symptoms to be worse than 
their usual state. Event-based definitions define an exacerbation as an event that leads the patient 
to seek medical advice, requires hospitalisation or necessitates treatment (generally a requirement 
for oral steroids or antibiotics). Event-based definitions of exacerbations are widely used in 
interventional clinical trials, however data from a longitudinal study of a cohort of COPD 
patients has shown that up to 50% of episodes of worsening of symptoms identified by symptom 
diary cards were not reported to the study investigators (3). Therefore an event-based definition 
may miss a substantial proportion of exacerbations that do not lead to a request for medical 
advice or treatment. The debate regarding the definition of an acute COPD exacerbation 
continues and further research is required to develop physiological or biological markers that 
provide a more objective means of defining an exacerbation. 
 
Epidemiology of COPD exacerbations 
 Most epidemiological data regarding COPD exacerbations is derived from hospital 
admission data or primary physician visits but these figures may be a considerable underestimate 
of the true incidence. Exacerbations are common events with a median of 1.2 to 2.4 exacerbations 
per patient per year (4), and the frequency of exacerbations increases with increased severity of 
the disease (5-7). Acute exacerbations of COPD are a major burden to health-care systems and 
their impact has increased over recent years. Since the mid-1990s emergency admissions for 
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COPD in the UK rose by 50% to a total of 98,000 in the year 2000 and one quarter of all hospital 
inpatient bed days used for treating acute respiratory disease are for COPD (8), amounting to 
nearly one million hospital bed days per year (9). In the USA there were over 660,000 hospital 
discharges for COPD in 1998.  A survey of COPD patients in the USA found that one-third had 
been hospitalised with COPD at some point in their life and 20% had visited the Emergency 
Department at least once in the past year (10). 70% of the health-care costs of the disease were 
estimated to be due to unscheduled hospitalisations due to acute exacerbations. In Canada COPD 
is the 4th most common cause of hospitalisation among men and the numbers of hospitalisations 
attributable to the disease are expected to double by the year 2015 (11). A hospital admission due 
to an acute COPD exacerbation carries a high risk of mortality and re-admission. A study of 
COPD patients in the USA who were hospitalised for an acute exacerbation, half of whom 
required intensive care, reported an in-hospital mortality rate of 11%, and six-month and one-year 
mortality rates of 33% and 43%, respectively. There was a 50% rate of readmission within six 
months after discharge (12). Prevention of exacerbations has now been recognised as a major 
therapeutic outcome for the evaluation of existing and new pharmacological agents for COPD. 
New therapies are urgently needed that will have a major impact on the morbidity, mortality and 
costs associated with COPD exacerbations.  
 
Aetiology of COPD exacerbations 
 Many exacerbations are associated with symptoms of infection of the tracheo-bronchial 
tree and bacteria have been considered the main infective cause of exacerbations (13). 
Determining the contribution of bacteria to exacerbations is difficult as COPD patients are often 
colonised with bacteria even when clinically stable (14). The proportion of patients with positive 
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bacterial cultures and an high bacterial load increases during exacerbations in most, although not 
in all studies (15-17). Newer molecular techniques have recently shown that colonisation is not a 
static condition and there is a frequent turnover of different strains of bacteria evoking specific 
host responses (18). Thus, it is likely that a change in the strain but not the organism may be 
responsible for the exacerbations. Therefore, previous studies lacking in the molecular 
characterisation of bacterial strains may have missed evidence of a new infection. Indeed, it has 
been documented that the acquisition of a new strain of colonising bacteria increases the risk of 
an exacerbation (19).  
In the last few decades the use of highly sensitive diagnostic methods, such as polymerase chain 
reaction (PCR), to evaluate the association between respiratory virus infections and COPD 
exacerbations has shown that viruses are responsible for a much higher proportion of 
exacerbations than was previously realised. In a study of the East London COPD cohort, 
respiratory viruses were detected in 39% of exacerbations, the most common being rhinoviruses 
that accounted for 58% of viruses (20). A respiratory virus was detected in around 50% of 
patients with severe COPD exacerbation admitted to hospitals in Germany and in Italy, with 
rhinovirus again being the most common (16, 21). In patients with very severe COPD 
exacerbations requiring intubation and mechanical ventilation viruses were identified in 47% of 
patients (22). At variance with bacterial infections, the respiratory viruses more commonly found 
at exacerbations were virtually absent in stable state (16, 23) suggesting that they play a relevant 
role in the aetiology of the acute episodes.  
A recent study has addressed the relative importance of viral versus bacterial infections, to the 
aetiology of severe (hospitalised) COPD exacerbations (Figure 1). Viral and/or bacterial infection 
was detected in 78% of COPD exacerbations, with viruses in 48.4% (6.2% when stable), bacteria 
in 54.7% (37.5% when stable). The more severe exacerbations were those in which viral and 
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respiratory viral infections may enhance the pathological processes associated with cigarette 
smoking and contribute to the lung pathology and loss of lung function associated with COPD. 
The type and the degree of activation of the different inflammatory cells recruited to the lung 
during COPD exacerbations has not been well characterised.  
CD8+ T lymphocytes, infiltrating both central (28) and peripheral airways (29) are a 
hallmark of COPD inflammation. These cells are further increased in the sputum during 
exacerbations (30).  
Among the possible causes of CD8+ recruitment in the airways, chronic viral infection of 
the lungs has been suggested to be important. Particular attention has been given to the possible 
role of latent adenoviral infection in the pathogenesis of stable COPD. Adenoviral DNA 
sequences encoding the E1A  protein are increased in the lung tissue of COPD patients as 
compared to smokers with normal lung function, suggesting latent adenoviral infection many 
occur in the lungs of COPD patients (31). Moreover, in COPD patients with emphysema the 
presence of adenoviral E1A protein in the alveolar epithelial cells was related to the severity of 
the emphysematous lesions and the number of CD8+ cells infiltrating the lung (32). These 
observations are consistent with the hypothesis that a persistent intracellular pathogen such as 
adenovirus may be capable of amplifying cigarette smoke-induced inflammation, possibly 
through interaction of viral proteins (such as E1A) with pro-inflammatory transcription factors 
[e.g. nuclear factor-κB (NF-κB) and activator protein (AP)-1)] (32). Recently it has also been 
documented that COPD patients in whom respiratory syncytial virus (RSV) was repeatedly 
detected in sputum over 2 years had faster lung function decline (33). Taken together these data 
indicate that in response to repeated/latent viral infections, an excessive recruitment of CD8+ T-
lymphocytes may occur in the tracheobronchial tree. The CD8+ driven inflammation can damage 
the lung in susceptible smokers leading to COPD progression (34). 
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Enhanced neutrophilic inflammation and sputum purulence have been considered for many years 
markers of bacterial aetiology of COPD exacerbations.  The traditional association of sputum 
purulence with bacterial infection is supported by the higher rate of isolation of bacterial 
pathogens in individuals with purulent sputum at presentation, with one study identifying a 
positive bacterial culture in 84% of purulent sputum compared with 38% if sputum was mucoid 
(35). Self-reported assessment of sputum purulence has also been investigated: bacterial cultures 
performed on sputum samples and protected brush specimens showed that self-reported sputum 
purulence was associated with a high yield of potentially pathogenic microorganisms with a 
positive predictive value of 77% (36). Gompertz et al have shown that when purulent sputum 
exacerbations are treated with antibiotics, resolution of exacerbations is associated with 
progressive reduction of neutrophilic airway inflammation (37). A number of studies documented 
that higher bacterial loads were more frequently associated with increased sputum neutrophils, 
supporting the concept that when bacteria are present at exacerbation, airway inflammation is 
higher in those samples where bacterial load is higher (17, 24).  IL-8 and TNF-α are potent 
neutrophilic chemoattractant chemokines with increased levels in sputum supernatants during 
COPD exacerbations. Although not in all studies, bacterial exacerbation have been associated 
with higher levels of sputum IL-8 and TNF-α , leading to enhanced neutrophil recruitment and 
activation (38, 39).  
Virtually all the studies that have found a relationship between bacterial infection and increased 
markers of neutrophilic inflammation in sputum samples and/or increased sputum purulence 
during exacerbation, did not take into account viral and/or viral/bacterial coinfections. Whether 
enhanced neutrophilic inflammation in the airways of COPD patients during exacerbation is a 
marker of bacterial infection has been debated in the last few years. Indeed, in experimental 
condition rhinovirus infection induces peripheral blood and sputum netrophilia in smokers and 
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COPD subjects (40). A recent study showed increased number of neutrophils in sputum during 
exacerbations and the neutrophilic response occurred irrespective of  the pathogen detected 
(bacteria vs viruses vs coinfection viruses+bacteria). The same study documented that purulent 
sputum at exacerbation was more frequent in infective exacerbations as compared to noninfective 
exacerbations but no difference was found between viral versus bacterial infections (16). 
Intriguingly a very recent study found that that COPD exacerbations associated with acquisition 
of new strains of bacteria, specifically H. influenzae, S. pneumoniae, M. catarrhalis and P. 
aeruginosa were associated with a more intense neutrophilic inflammatory response in the 
airway, as well as more intense systemic inflammation, compared to exacerbations not associated 
new strain acquisition and inflammatory cell profile at exacerbation (41).  
One of the future major task in the field of exacerbation will be to identify inflammatory or 
specific biological markers able to tell us whether bacteria are in fact responsible for the ongoing 
exacerbation. This would be extremely helpful in addressing an appropriate use of antibiotic 
treatments. With this aim, several specific markers of bacterial infections have been tested in the 
last few years. A promising role of procalcitonin to define patients with a COPD exacerbation 
with a higher likelihood of bacterial infection has been recently suggested. Procalcitonin is a 
small (13-kD) protein normally undetectable in plasma that increases markedly in bacterial 
infections (42). Data from single-center, cluster-randomized, single-blinded study suggests that 
procalcitonin-guided therapy can be safely used to reduce antibiotic use in patients admitted to 
the hospital with COPD exacerbation at a low likelihood of bacterial infection (43).  
Few studies have investigated the role of respiratory virus infection in COPD exacerbations, and 
very few have looked at the relationship between viral infections and airway inflammation at 
exacerbations.  
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One study found increased sputum IL-6 in viral associated acute episodes as compared to non 
viral exacerbations (23).  Intriguingly, and only recently, it has been documented that plasma 
fibrinogen levels, a marker of systemic inflammation and a recognized independent risk factor for 
cardiovascular disease, are higher in viral associated COPD exacerbation (44). This indicates that 
respiratory viral infections are associated with an increased systemic inflammation and might 
predispose to an increased risk of cardiovascular disease. Bacterial and virus infection can 
synergistically interact to increase the severity of inflammatory response. Indeed, it has been 
shown that rhinovirus and Haemophilus influenzae coinfection at  exacerbations is associated 
with increased levels of serum IL-6 (24). In this situations, i.e. viral and bacterial coinfection, 
exacerbations are more severe both in term of clinical and lung function parameters (16, 24). 
Similarly, levels of endothelin (ET)-1, a  potent vasoconstrictor and bronchoconstrictor peptide 
with  important pro-inflammatory activities in the airways, tend to be higher during COPD 
exacerbation associated with viral or chlamydial infection both in sputum and in plasma (45).  
A recent study investigated the relative importance of viral and bacterial infection in COPD 
exacerbations and their relationship with airway inflammation (16).  At variance with 
neutrophils, sputum eosinophils were significantly elevated at exacerbation only in the subgroups 
with viral infections (Figure 2). In this study, sputum eosinophils at exacerbation could predict a 
positive viral detection in sputum with a sensitivity of 0.82 and a specificity of 0.77 for 
eosinophil counts of 1.68 x 106/g or greater (best cut-off point).  Similarly, sputum eosinophil 
count increases from stable conditions to exacerbation of 0.3 x 106/g or more predicted a virus-
associated COPD exacerbation with a sensitivity of 0.87 and a specificity of 0.81. Sputum 
eosinophilic cationic protein (ECP) levels in the supernatant of samples obtained from 
exacerbations associated with viral infection, either with or without a bacterial coinfection, were 
significantly higher as compared with virus-free exacerbations. This data suggests that sputum 
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Mechanisms of virus induced COPD exacerbations 
At variance with asthma in which several in vitro and in vivo studies have investigated the 
mechanisms that lead to exacerbation after viral infection of the airways (48, 49), very few data 
are available for COPD.  By contrast, several mechanisms have been proposed to explain how 
bacterial infection can affect airway inflammation leading to COPD exacerbations. These include 
induction of mucus hypersecretion (50), reduction of ciliary beat frequency (51) and 
enhancement of neutrophilic inflammation (52). In particular, H influenzae can cause direct 
epithelial damage and its endotoxin has been shown to increase epithelial expression of the pro-
inflammatory cytokines IL-6, IL-8, and TNF-α in vitro, providing potential mechanisms to 
upregulate inflammation and specifically neutrophilic inflammation (52). This is in line with in 
vivo data showing that COPD patients with a positive bacterial culture of potential pathogenic 
microbes have higher concentrations of TNF-α and increased neutrophils in the airways (38, 53).  
Activated neutrophils degranulate, resulting in the release of elastases, oxidants, and proteases. 
Proteases and oxidants can damage the epithelium, reduce ciliary beat frequency, stimulate 
mucus secretion by mucus-secreting cells, and increase the permeability of the bronchial mucosa. 
These changes, especially in the small airways, may adversely affect airflow leading to increased 
dyspnoea, as well as increased  mucus secretion and sputum purulence. In addition, neutrophil 
elastase and oxidants have been shown to increase epithelial mucin mRNA and protein gene 
expression in vitro. Neutrophil elastase is a major driver of lung injury, thus elevated levels of 
this enzyme seen in bacterial exacerbations could contribute significantly to the loss of lung 
function seen in COPD (54). Bacterial components, such as lipopolysaccharide (LPS), through 
their interaction with toll-like receptors can activate nuclear transcriptor factor κB  (NF-κB) (55). 
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Activation of NF-κB leads to the production of several cytokines, chemokines and adhesion 
molecules involved in the inflammatory cascade that characterised COPD exacerbation (56). 
Interestingly, a recent study found increased NF-κB activation in sputum macrophages during 
COPD exacerbations (57).  
Although in vitro models can provide important insights into the molecular mechanisms of 
inflammatory and immune responses to bacterial infection, the in vitro data require validation in 
vivo models.  Unfortunately, despite bacterial infections being considered the most important 
cause of COPD exacerbations there is still  no in vivo model of bacteria induced COPD 
exacerbation.  
Despite growing clinical evidence for a role of respiratory viral infections in the pathogenesis of 
COPD exacerbations, the precise mechanisms of interactions between respiratory virus and lower 
airway inflammation and of host resistance against respiratory viruses are poorly understood (56). 
Most of the data available relate to rhinovirus, i.e.  the respiratory virus that appear to be more 
frequently involved in COPD exacerbations (5, 16, 21). The major group of rhinoviruses 
(accounting for 90% of total rhinovirus types) attaches to airway epithelium through intercellular 
adhesion molecule 1 (ICAM-1) (58). Interestingly, rhinovirus infection induces expression of its 
own receptor (ICAM-1) (59), which might promote inflammatory cell recruitment and activation. 
Indeed, since ICAM-1 is over-expressed in the bronchial mucosa of patients with stable chronic 
bronchitis (60), one of the possible mechanisms for increased susceptibility to infections and for 
increased airway inflammation is rhinovirus-induced ICAM-1 upregulation in bronchial 
epithelial cells. In vitro data documents that experimental rhinovirus infection of bronchial 
epithelial cells induces pro-inflammatory mediators including cytokines and chemokines such as 
IL-6, CXCL8, IL-11,  GM-CSF, CCL5, 5-lipoxygenase (5-LO), 5-LO activating protein (FLAP) 
and cyclooxygenase (COX)-2, endothelin and adhesion molecules (56). Thus rhinovirus infection 
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of bronchial epithelial cells can lead to the production of inflammatory mediators able to induce 
both neutrophilc and eosinophilic inflammation, in line with clinical observations showing that 
neutrophilic and eosinophilic inflammatory responses can occur in vivo following rhinovirus 
infection. Interestingly, bronchial eosinophilia has been described some years ago in bronchial 
biopsies of healthy subjects experimentally infected with rhinovirus (61).  
In vitro rhinovirus infection of human bronchial epithelial cells increases their MUC5AC (one of 
the major mucins in the sputum) synthesis and release (62). This could be relevant to explain the 
increased amount of sputum observed in some patients during COPD exacerbations. 
Rhinovirus infection induces increased production of superoxide anion in bronchial epithelial 
cells and this event is a crucial step for the activation of NF-κB and the following production of 
proinflammatory cytokines, chemokines and adhesion molecules (63). Reducing agents inhibit 
both rhinovirus-induced oxidant generation and inflammatory mediator production and release 
(63). This data suggests that the inhibition of intracellular oxidative stress may be a potential 
therapeutic target for the treatment of virus induced COPD exacerbations.  
It has been recently shown that early activation of mitogen-activated protein (MAP) kinase p38 is 
a key regulatory event of rhinovirus-induced pro-inflammatory transcription factor activation and 
cytokine/chemokines transcription both in bronchial epithelial cells and monocyte/macrophages 
(64, 65). These mechanisms could be a target for inhibition of airway inflammation associated 
with rhinovirus infection.  
To validate in vitro observations, the development of an in vivo models is necessary. Thus the 
recent development of a human experimental model of rhinovirus-induced COPD exacerbations 
represents an innovative tool that will offer the opportunity to deeply elucidate the inflammatory 
and immunological mechanisms that lead COPD patients to exacerbate after respiratory virus 
infections and to identify novel possible pharmacological targets (66). This model shows that 
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experimental rhinovirus infection in COPD patients induces symptoms, lung function changes, 
increased peripheral blood total leukocyte count, increased peripheral neutrophil and increased 
sputum neutrophil number (40, 66) similar to that observed in naturally-occurring exacerbations. 
In COPD this is so far the only scenario in which a specific aetiology has been experimentally 
proven to induce an exacerbation. 
 
Susceptibility to virus infections in COPD patients 
There is solid evidence of impaired innate (67, 68) and possibly acquired (69, 70) immune 
responses to viral infection in asthmatic patients. Whether COPD patients are more susceptible to 
virus infection as compared to normal subjects is still debated. A recent study documented that 
patients with frequent (>2.5/year) COPD exacerbation have more frequent episodes of naturally 
occurring colds as compared to patients with infrequent exacerbations (71). These results suggest 
that COPD subjects with frequent exacerbations may represent a subgroup particularly 
susceptible to viral infections, but they do not determine whether this susceptibility relates to the 
general COPD population. Intriguingly patients experiencing frequent colds had a significantly 
higher exposure to cigarette smoke (71). Recently, using a murine model of cigarette smoke 
exposure, it was demonstrated that virus infections in combination with tobacco smoke decreased 
the number of dendritic cells in the lung and also altered the costimulatory molecule expression 
profile on these cells, that are believed to be fundamental  to the initiation of adaptive immune 
response (72). In the same study it was also that mice exposed to smoke after adenovirus 
infection had a  decreased T cell-mediated antiviral immune response, as documented by reduced 
infiltration of activated CD4 and CD8 T cells, in the lungs (72). Thus cigarette smoke, possibly 
  
46 
 
via alteration of both innate and adaptive immune responses, can contribute to the increased 
susceptibility of COPD patients to viral infections (73). 
Another possible mechanism leading to increased susceptibility is related to up regulation 
of ICAM-1, the receptor for the major group of human rhinoviruses. Latent expression of 
adenoviral E1A protein in alveolar epithelial cells of patients with pulmonary emphysema may 
increases ICAM-1 expression and this could be a potential mechanism for a greater susceptibility 
to rhinovirus infection of COPD patients (32).  
Finally, solid evidence exists that the surface of the bronchial mucosa of patients with 
COPD is chronically colonised with bacteria, and the bacterial load is related to the intensity of 
the airway inflammation and to disease progression (74). Moreover patients with a history of 
frequent exacerbations have a higher incidence of bacterial colonisation. Thus, given that viral 
infections are one of the most frequent causes of COPD exacerbation these results indicate that 
chronic bacterial colonisation could contribute to the increased susceptibility of COPD patients to 
viral infection, for example by increasing ICAM-1 expression on the surface of the bronchial 
epithelial cells (75). Further studies are required to investigate the interaction between chronic 
bacterial colonisation and respiratory viral infection and in particular whether chronic bacterial 
colonisation can increase viral infection susceptibility or alternatively that viral infection can 
increase the airway bacteria load leading to COPD exacerbations.  
 
Conclusions 
COPD is a major health problem worldwide with rising prevalence and mortality. The 
major morbidity, mortality and health care costs of COPD are due to exacerbations (13).  
Thanks to the development of highly sensitive diagnostic tools, the interaction between 
respiratory viruses and bacteria has emerged as a leading cause of COPD exacerbations (16, 24). 
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However, the mechanisms responsible for the interaction between these airway pathogens and the 
inflammatory processes in causing COPD exacerbations are still largely unknown (56).  
The recent development of the first human model of virus induced COPD exacerbation, is 
rapidly advancing our knowledge on these interactions (66). Improved understanding of the host-
pathogen interaction in the lower airways in COPD patients will undoubtedly facilitate the 
identification of novel pharmacological targets that will provide opportunities to develop new 
treatments for COPD exacerbations. 
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Summary and Aim 
Acute exacerbations are the major cause of morbidity in asthma. The majority are precipitated by 
rhinovirus infections. Asthmatics have increased susceptibility to rhinovirus infections and risk of 
invasive bacterial infection. The mechanisms of this increased susceptibility are unknown. 
The novel type III interferon-λs exhibit some properties similar to type I interferons but their 
activity in protecting against rhinovirus infections and in the pathogenesis of asthma 
exacerbations is unknown.  
Here we investigated the role of interferon-λs in rhinovirus infection of human bronchial 
epithelial cells in vitro, their production in asthmatic and normal subjects in response to 
rhinovirus infection of primary bronchial epithelial cells and both rhinovirus & 
lipopolysaccharide (LPS) stimulation of bronchoalveolar lavage cells ex vivo. Finally we 
investigated the role of interferon-λ production in the pathogenesis of rhinovirus infection and 
asthma exacerbations in vivo using human experimental infections in asthmatic and normal 
subjects.  
We show that interferon-λs are induced by and are anti-viral against rhinovirus infections in 
vitro. In asthma their induction by both rhinovirus infection and lipopolysaccharide is deficient. 
Finally deficient production correlated with severity of rhinovirus induced cold symptoms, lung 
function impairment and virus load in vivo. These data identify an important novel mechanism in 
the pathogenesis of asthma exacerbations and in increased susceptibility to viral and bacterial 
infections in asthma and suggest new approaches to prevention and/or treatment of asthma 
exacerbations.  
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Recently, deficient interferon-β production following in vitro rhinovirus infection of primary 
bronchial epithelial cells from asthmatic subjects has been reported (1). Although a novel 
observation providing some insight into mechanisms of increased susceptibility to virus infection 
in asthma, this study investigated only interferon-β, in a single cell type, bacterial stimuli were 
not studied and most importantly, relationship with clinical illness severity was not investigated. 
Here we have hypothesized that in asthma there could be deficiency in components of innate 
immune responses other than interferon-β production that would include other respiratory cells 
and be observed in response to both virus and bacterial infection. Finally we hypothesized that 
deficient production would be related to clinical illness severity in vivo. 
The 13 α interferons and one β interferon are expressed on chromosome 9 and are classed as type 
I interferons as they signal through a common type I interferon receptor and have similar biologic 
properties in innate host defense. The single class II interferon is interferon-γ, which signals 
through the interferon-γ receptor and is important in both innate and acquired immunity. A novel 
class of interferons have recently been discovered and named type III interferons: interferon-λ1 
(also known as interleukin [IL]-29) and interferon-λ2/3 (IL-28A/B) which are expressed on 
chromosome 19 and signal through a unique interferon-λ-specific receptor(2, 3). Similar to type I 
interferons, they induce interferon stimulated genes, signal via Jak/Stat pathways and have 
antiviral activity in vitro(2, 3). They also exhibited antiviral activity in vaccinia virus infected 
mice(4). However, their role in the pathogenesis of rhinovirus infection and in asthma is 
unknown. 
We therefore investigated the role of interferon-λs in rhinovirus infection of human bronchial 
epithelial cells in vitro, their production in asthmatic and normal subjects in response to 
rhinovirus infection of primary bronchial epithelial cells and both rhinovirus & 
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lipopolysaccharide (LPS) stimulation of bronchoalveolar lavage cells ex vivo. Finally we 
investigated the role of interferon-λ production in the pathogenesis of rhinovirus infection and 
asthma exacerbations in vivo using human experimental infections in asthmatic and normal 
subjects.  
 
Results 
 
Interferon lambdas are induced by rhinovirus infection of bronchial epithelial cells, 
monocytes and macrophages  
First, to determine whether interferon-λs are induced by rhinovirus infection, we investigated 
their expression in the BEAS-2B human bronchial epithelial cell line. We developed separate 
quantitative PCRs for human interferon-λ1 and -λ2/3 as they are only 80% homologous, but a 
single assay for interferon-λ2/3 as they are 96% homologous(2, 3). Interferon-λs were not 
expressed in uninfected cells, but rhinovirus-16 infection significantly induced mRNA expression 
for interferon-λ1 and interferon-λ2/3 peaking at ~4 logs 8 hours post infection and remaining 
significantly increased 24 & 48 hours after infection. Induction was dose responsive, increasing 
from ~2 logs at a multiplicity of infection (MOI) 0.4 to ~4 logs at a MOI of 10.  
There are at least 100 different rhinovirus serotypes, separated into a major group (90%, 
including rhinovirus-16) which  use ICAM-1 as cellular receptor(5) and a minor group using the 
LDL receptor(6). To determine whether interferon-λ induction was rhinovirus receptor and 
serotype independent, we performed similar experiments with another major group (rhinovirus-9) 
and a minor group (rhinovirus-1B) rhinovirus serotype. Infection with either induced interferon-
λ1 and -λ2/3 to similar degrees to that observed with rhinovirus-16, indicating induction was both 
rhinovirus receptor and serotype independent. Also, UV-inactivation of all three serotypes 
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completely blocked induction of interferon-λ1 and -λ2/3, confirming that induction was 
rhinovirus replication dependent. 
To confirm that rhinovirus induction of mRNA expression was accompanied by protein 
production, we developed an ELISA specific for interferon-λs and assessed protein production in 
the supernatants of the same experiments. Rhinovirus-16 infection induced interferon-λ protein 
production in a dose responsive manner. 
Macrophages and/or dendritic cells also contribute to type I interferon production and therefore to 
the antiviral state in the airway(7). To investigate whether other cell types were important sources 
of interferon-λ production in response to rhinoviruses infections, we next investigated production 
in response to rhinovirus infection of peripheral blood mononuclear cells and observed similar 
rhinovirus induction of interferon-λ mRNA expression and protein production.  
To determine whether induction was also observed in differentiated macrophages and was also 
replication dependent in non-epithelial cells, we investigated interferon-λ protein production in 
monocyte derived macrophages in response to UV-inactivated and live rhinovirus-16. Significant 
induction of interferon-λ protein production was only observed in cells infected with live virus, 
confirming replication dependent production in macrophages.  
 
Interferon lambdas protect bronchial epithelial cells against rhinovirus infection in vitro 
We next investigated whether interferon-λ is antiviral in the context of rhinovirus infection of 
bronchial epithelial cells. BEAS-2B cells were infected with rhinovirus-16 in the presence or 
absence of interferon-λ1 and virus replication assessed by quantifying rhinovirus viral RNA 
production in cell lysates and virus release into cell supernatants. Interferon-λ1 significantly 
suppressed viral RNA production and virus release (Figures 2), confirming anti-rhinoviral 
activity of this protein in bronchial epithelial cells. 
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Deficient interferon-λ production in human primary bronchial epithelial cells from 
asthmatic compared to normal subjects and relationship to rhinovirus replication in vitro  
As we have previously reported deficient rhinovirus induced interferon-β production in asthmatic 
primary bronchial epithelial cells(1), we next wished to determine whether interferon-λ1 and 
interferon-λ2/3 induction occurred in response to rhinovirus infection of primary bronchial 
epithelial cells, and if so, whether this was deficient in asthmatic compared with normal cells.  
First we investigated rhinovirus replication in these cells by assessing viral RNA production in 
cell lysates. As previously reported(1), at 8 hours after infection we found significantly (10 fold) 
increased rhinovirus replication in primary bronchial epithelial cells from asthmatic compared 
with normal subjects (Figure 3A). Rhinovirus induction of interferon-λ1 and interferon-λ2/3 
mRNA expression in primary bronchial epithelial cells was confirmed in the same cell lysates in 
cells from both normal and asthmatic volunteers, however, induction of both interferon-λ1 and 
interferon-λ2/3 was significantly lower in asthmatic compared with normal subjects, confirming 
that rhinovirus induction of interferon-λs occurs in the relevant primary cells, but is deficient in 
asthma (Figure 3B).  
To determine whether interferon-λ1 and interferon-λ2/3 production was related to virus 
replication in primary cells, we next investigated correlations between interferon-λ expression 
and virus replication. Expression of interferon-λ1 and interferon-λ2/3 mRNA were strongly 
inversely related to viral RNA copy number, indicating that interferon-λ induction in response to 
rhinovirus infection of primary bronchial epithelial cells is strongly related to virus replication. 
The deficient induction in asthmatic cells was also very clearly related to virus replication in 
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vitro, as the asthmatic and normal data were clearly separated, with asthmatics having greater 
virus load and lower interferon-λ expression. 
Induction of interferon-λ1 and interferon-λ2/3 mRNA by rhinovirus infection of primary 
bronchial epithelial cells resulted in induction of interferon-λ protein production in cells from 
both normal and asthmatic volunteers. Protein production in supernatants of cells from asthmatic 
volunteers was also significantly impaired compared with normal volunteers. The relationship 
between interferon-λ protein production and rhinovirus replication was again investigated and 
found to be significantly inversely correlated and once again the asthmatic and normal data were 
clearly separated, with asthmatics having greater virus load and lower interferon-λ production 
(Figure 3C). 
These data confirmed interferon-λ1 and interferon-λ2/3 are induced by rhinovirus infection of 
primary bronchial epithelial cells, that induction of both mRNA and protein is deficient in cells 
from asthmatic subjects and that induction is strongly related to rhinovirus replication in vitro. 
 
Deficient rhinovirus induced interferon-λ production from bronchoalveolar lavage cells 
from asthmatic compared to normal subjects and relationship to illness severity and virus 
load in vivo  
We next wished to investigate induction of interferon-λs and their relation to clinical illness 
severity in vivo. As the only useful animal model of rhinovirus infection is in chimpanzees (8, 9), 
these experiments were carried out using human experimental rhinovirus infections in a different 
group of normal and asthmatic subjects. Also, to determine whether deficient interferon 
production in asthma was restricted to epithelial cells, we wished to investigate whether 
interferon-λ induction in asthma was also deficient in cell types other than bronchial epithelial 
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cells. Having shown earlier that macrophages were robust producers of interferon-λ, we studied 
bronchoalveolar lavage cells, which are normally ~90% macrophages. 
Bronchoalveolar lavage cells were obtained from asthmatic and normal volunteers and incubated 
ex vivo. Incubation with live rhinovirus-16 significantly induced interferon-λ protein production 
from both normal and asthmatic cells, this induction was virus-specific, as no induction was 
observed in cells incubated with medium or inoculum from which the virus had been removed by 
molecular weight filtration(10). We then compared induction of interferon-λ in cells from 
asthmatic and normal subjects and confirmed that, like bronchial epithelial cells, rhinovirus 
induction in bronchoalveolar lavage cells was also deficient in asthma (Figure 4A). 
To determine whether rhinovirus induced interferon-λ production was related to clinical illness 
severity and virus load in vivo, the same volunteers were experimentally inoculated with 
rhinovirus-16 two weeks after the ex vivo studies. We observed a significant inverse correlation 
between interferon-λ concentrations in supernatants of bronchoalveolar lavage cells infected with 
rhinovirus ex vivo, and severity of cold symptoms following in vivo infection, confirming that 
rhinovirus induction of interferon-λ was related to symptom severity in vivo. A similar inverse 
correlation was observed between interferon-λ concentrations and bronchoalveolar lavage virus 
load during in vivo infection (Figure 4B).  
A relationship between interferon-λ production and severity of rhinovirus induced asthma 
exacerbations was also demonstrated by a significant inverse relationship between interferon-λ 
concentrations and severity of reductions in lung function during in vivo infection (Figure 4C). 
Even with these in vivo data, the asthmatic and normal data were once again remarkably 
separated, with asthmatics having greater symptoms, virus load and lung function impairment 
and lower interferon-λ production. 
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Deficient LPS induced interferon-λ production from bronchoalveolar lavage cells from 
asthmatic compared to normal subjects and relationship to lung function in vivo  
Asthmatics are at increased risk of invasive bacterial infection(11), through unknown 
mechanisms. Finally, to gain insight into possible mechanisms, bronchoalveolar lavage cells 
obtained from the same asthmatic and normal volunteers were incubated ex vivo with bacterial 
LPS and interferon-λ production assessed. These experiments were also designed to provide 
some initial insight to possible mechanisms of deficient interferon-λ production in asthma as Toll 
like receptor (TLR)3 mediates anti rhinovirus activity(12) as well as interferon-λ production(13) 
in bronchial epithelial cells, while LPS is a ligand for TLR4(14).  
Significant induction of interferon-λ by LPS was observed in both normal and asthmatic subjects 
and induction was significantly impaired in asthmatic relative to normal subjects (Figure 5A). A 
relationship between LPS induced interferon-λ production and severity of rhinovirus induced 
asthma exacerbations was also demonstrated by the finding of a significant inverse relationship 
between interferon-λ concentrations in supernatants of bronchoalveolar lavage cells stimulated 
with LPS ex vivo, and severity of reductions in lung function in vivo (Figure 5B). 
 
Discussion 
Acute attacks of asthma are a serious and common medical problem poorly met by current 
medication(15-17). New therapies are needed, however although rhinovirus infection is the major 
precipitant(18-20), the pathogenesis is poorly understood(21). Innate immune responses are 
critical in host defense against viral infections and asthmatics have increased susceptibility to 
naturally occurring rhinovirus infections(20). The mechanisms of this increased susceptibility are 
unknown. Here we found that type III interferons were strongly induced by rhinovirus in 
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bronchial epithelial cells and macrophages and were antiviral against rhinovirus infection in vitro. 
We further demonstrated their induction in response to ex vivo rhinovirus infection of both 
primary bronchial epithelial and bronchoalveolar lavage cells and importantly, that this induction 
was deficient in both cell types derived from asthmatic subjects. We highlighted the importance 
of these interferons in host defence against rhinovirus infection by demonstrating strong 
relationships between interferon-λ production and rhinovirus replication ex vivo, and most 
importantly, with severity of clinical symptoms, reductions in lung function and virus load in 
vivo. These data identify a novel mechanism of increased susceptibility to rhinovirus infection in 
asthma and suggest replacement/augmentation of innate interferon production as a novel 
approach to treatment/prevention of asthma exacerbations. 
The interferon-λs are already known to induce some interferon stimulated genes, signal via 
Jak/Stat pathways and have antiviral activity in vitro(2, 3) and in vaccinia virus infected mice(4). 
These data suggest they are likely important in host defense, however, their role in the 
pathogenesis of respiratory virus infections is poorly understood and in asthma, unknown. One 
previous study reported induction of interferon-λs in response to respiratory syncytial virus 
infection of an alveolar cell line and monocytes(22), we extend these observations to demonstrate 
their induction by rhinovirus infection of a bronchial epithelial cell line as well as primary human 
peripheral blood monocytes and monocyte derived macrophages. We then demonstrated that 
interferon-λ induced the ISGs CCL5 and CXCL10, which are implicated in the pathogenesis of 
rhinovirus infections(23, 24), and confirmed that interferon-λ had antiviral activity in suppressing 
rhinovirus replication in bronchial epithelial cells. Since rhinovirus infections are the major cause 
of acute exacerbations of asthma(18-20), these properties strongly suggest interferon-λ 
production is likely important in host defense against rhinovirus induced asthma exacerbations. 
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We next investigated the importance of interferon-λs in increased susceptibility to rhinovirus 
infection in asthma(20). Initially we investigated induction of interferon-λs in response to ex vivo 
rhinovirus infection of primary bronchial epithelial cells (from asthmatic and normal volunteers), 
as these are the natural host cell for rhinovirus infection in the lower respiratory tract(25). We 
confirmed rhinovirus induction of interferon-λs in both subject groups, confirming rhinovirus 
induction in the natural host cells ex vivo. As we had previously observed(1), rhinovirus 
replication was confirmed increased in the primary bronchial epithelial cells from asthmatic 
volunteers and induction of interferon-λs by rhinovirus infection of asthmatic primary bronchial 
epithelial cells was deficient compared to normal cells and was very strongly inversely related to 
rhinovirus replication in vitro. The strength of these relationships is impressive, despite the small 
numbers of subjects studied (9 in each group). However, most impressive is the complete 
separation between the asthmatic and normal subjects (open), as the asthmatics had uniformly 
lower interferon-λ production and higher virus loads and vice versa in the normals. Such clear 
separation in studies of human biology is rare and these data combined strongly attest to the 
likely biologic importance of these relationships and of deficient interferon-λ production in the 
pathogenesis of rhinovirus infections. 
Our previous study of interferon-β(1) and our findings above with interferon-λs are restricted to 
primary bronchial epithelial cells, possibly suggesting a cell type-specific defect in interferon 
production in asthma. We therefore wished to determine whether deficient interferon-λ 
production was also observed in a different cell type also relevant to lung host defense. We 
initially demonstrated that rhinovirus induced interferon-λ in monocytes and macrophages in 
vitro. We then recruited a further group of asthmatic and normal subjects and confirmed that 
interferon-λ was induced by rhinovirus infection of primary bronchoalveolar lavage cells (~90% 
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macrophages) ex vivo. Interferon-λ induction by rhinovirus was also found deficient in 
bronchoalveolar lavage cells from asthmatic subjects, confirming that this deficiency was not 
restricted to bronchial epithelial cells. 
We next wished to determine whether deficient interferon-λ production was related to clinical 
illness severity and virus load in vivo. One of the major obstacles to understanding the 
pathogenesis of rhinovirus infections has been the lack of a useful small animal model(8, 9). We 
therefore next investigated the role of interferon-λ in vivo in the same second group of asthmatic 
and normal volunteers, who were infected experimentally with rhinovirus-16 two weeks after 
their initial bronchoscopy and clinical illness severity assessed with symptom diary cards and 
lung function recording. A further bronchoscopy was carried out on day 4 of the experimental 
infection to determine virus load in the bronchoalveolar lavage during in vivo infection. 
Interferon-λ production was significantly inversely correlated with both common cold symptoms 
and virus load, confirming in vivo, the importance of interferon-λs in host defence against 
rhinovirus infection 
To determine whether interferon-λs are important in the pathogenesis of rhinovirus induced 
asthma exacerbations, we also investigated the relationship between interferon-λ production and 
severity of reductions in lung function in response to rhinovirus infection. A significant 
correlation was observed. As with the ex vivo data, the strength and significance of the 
relationships with small subject numbers (4/5 asthmatic and 8 normal), as well as the separation 
between asthmatic and normal volunteers observed in all three relationships, was remarkable for 
human in vivo data. These data therefore very strongly implicate deficient interferon-λ  
production as an important novel mechanism in the pathogenesis of asthma exacerbations.  
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As asthmatic subjects have also been recently shown to be at increased risk of invasive bacterial 
infection(11), through unknown mechanisms, we then wished to determine whether interferon-λ 
production was deficient in asthma when studying a stimulus relevant to bacterial infections. 
These experiments confirmed interferon-λ production in response to LPS was also deficient in 
bronchoalveolar lavage cells from asthmatic compared to normal subjects and was inversely 
related to lung function impairment in vivo. With our previous study(1), these experiments 
indicate that the deficiencies in components of innate immune responses in asthmatic subjects are 
surprisingly broad and involve defective responses in two interferon families. In the present 
study, interferon-λ deficiency has also been observed in different lung cell types, as well as in 
response to both a bacterial stimulus and rhinovirus infection.  
While replacement of interferons -β or -λ in asthma are possible new therapeutic options, in order 
to explore further therapeutic options, it is highly desirable to understand the mechanisms of 
deficient interferon-β and -λ production in asthma. While knowledge regarding interferon 
deficiency in asthma was restricted to interferon-β, polymorphism(s) in that gene represented an 
attractive possible explanation, however, with deficiency now involving 4 genes on two different 
chromosomes (9 for interferon-β and 19 for the lambdas(2, 3)), this explanation seem less likely. 
There has been much recent interest in signalling pathways in innate anti-viral immunity. In 
response to viral infection, TLR3(12, 26-28), 7(29-32), 8(29-31) and 9(30, 33) and PKR (34-36) 
and RIG-I (29, 37, 38) have been implicated in induction of type I interferons. Much less is 
known about interferon-λ, however it has recently been demonstrated that TLRs 3, 4, 7, 8 and 9 
mediate virus induction of interferon-λs, as well as α/β interferons(30). Induction of interferon-
λs via TLRs 7-9 was shown to be mediated by the IL-1 receptor associated kinase-4 (IRAK-4), 
however, that via TLR3 and 4 was IRAK-4 independent(30). IRAK-4 deficiency is a novel 
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deficiency in TLR signalling associated with human disease(30), it may therefore seem an 
attractive possible mechanism to explain interferon-λ deficiency in asthma. However, LPS is a 
ligand for TLR4(14, 39, 40) and TLR3 mediates interferon-λ production(13) and anti-rhinoviral 
activity(12) in respiratory epithelial cells, while interferon-λ induction via TLR3 and 4 was 
IRAK-4 independent(30), thus IRAK-4 deficient signalling appears an unlikely explanation for 
the deficiencies we have observed in asthma.  
TLRs activate downstream effectors through numerous other adaptors including MyD88, IRAK-
1, Toll/IL-1 receptor domain-containing adaptor-inducing interferon-β (TRIF), TNF receptor-
associated factor (TRAF) 6, as well as downstream kinases. TRAF3 has recently been shown to 
be an important component of both TLR-dependent and TLR-independent viral recognition 
pathways(41, 42). Deficiency in any of these signalling intermediates or of transcription factors 
involved in the induction of the interferon-β gene (involving NF-B, IRF-3 and ATF/c-Jun 
transcription factors)(43-45) could potentially explain deficient production of interferon-β in 
asthma. However, with the exception of induction via TLR7-9 in blood cells and fibroblasts 
being known to be IRAK-4 dependent(30), the signalling intermediates and transcription factors 
mediating induction of the interferon-λs by virus infections are unknown, as are the mechanisms 
of induction of these interferons and interferon-β in response specifically to rhinovirus infection 
of bronchial epithelial cells. These mechanisms now require careful exploration.  
Another possible explanation could involve impaired innate interferon responses in asthma being 
due to inadequate maturation of these responses consequent upon reduced exposure to infectious 
disease in early life. Little is known regarding development of type I and type III interferon 
responses but reduced exposure to infectious disease in early life has been implicated in the 
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increasing prevalence of asthma(46, 47). Related to this, wheezing is much more common in 
children than in adults(48), and more wheezing in children is related to virus infections(18-20). 
These data suggest that the deficiencies we have observed in adult asthma, could be even more 
profound in children and may help to explain the increased incidence of virus induced wheeze in 
children. Studies investigating these possibilities are required. 
In conclusion, our findings identify a potentially important and novel mechanism in the 
pathogenesis of asthma exacerbations and in increased susceptibility to viral and perhaps 
bacterial infections in asthma, suggest new approaches to prevention and/or treatment of asthma 
exacerbations and open new avenues for investigation to increase our understanding of disease 
pathogenesis as well as reasons for its increasing prevalence.  
 
 Methods 
 
BEAS-2B and virus culture 
BEAS-2B bronchial epithelial cells (European Collection of Cell Cultures [ECACC]), were 
grown in RPMI 1640 media supplemented with Glutamax (Invitrogen, Paisley UK), with 10% 
foetal calf serum (FCS) buffered with 1% sodium bicarbonate and 2.5% HEPES (all Invitrogen) 
and grown in a humidified incubator at 37ºC with 5% CO2. Major group rhinovirus serotypes 
rhinovirus-16 and rhinovirus-9 and minor group serotype rhinovirus-1B were grown in Ohio 
HeLa cells (ECACC) and stocks prepared as HeLa lysates at 1x107 TCID50/mL(10). The 
identities of each rhinovirus were confirmed by neutralisation using serotype specific antibody 
(ATCC). UV inactivation and filtration of virus were performed as previously described(10).   
 
Rhinovirus infections and antiviral assay  
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BEAS-2B cells were seeded at 1.7x105 cells/mL, then placed in RPMI 1640 media supplemented 
with 5% FCS (all Invitrogen)  overnight, prior to infection with rhinovirus-16, rhinovirus-9 or 
rhinovirus-1B (multiplicity of infection [MOI] of 2 unless otherwise stated ), for 1 hour at room 
temperature with shaking. Virus preparations were removed and 1 mL fresh medium added. 
Plates were incubated at 37ºC. Both cell lysates and supernatants were harvested at various time 
points and stored at –80°C. To investigate the antiviral effect of interferon-λ1, BEAS-2B cells 
were infected with rhinovirus-16 for 1 hour, washed and medium replaced with or without 
different doses of interferon-λ1 (Peprotech). Cells and supernatants were harvested at 24 hours. 
Viral RNA in cell lysates was measured by TaqMan® RT-PCR and infectious virus in 
supernatants measured by viral titration in Ohio-HeLa cells. 
 
Biological effect of interferon-λ 
To investigate the biological effects of interferon-λ1, BEAS-2B cells were seeded and treated for 
24hrs with or without different doses of interferon-λ1 (Peprotech) and supernatants harvested for 
ELISA. To investigate the biological effects of interferon-λ1 with rhinovirus infection, BEAS-2B 
cells were seeded and treated with medium alone or infected with rhinovirus-16 for 1 hour, 
washed and medium replaced for 24hrs with or without different doses of interferon-λ1 
(Peprotech) and supernatants harvested for ELISA.  
 
Quantitative RT-PCR 
Total RNA was extracted (RNeasy Kit, Qiagen) and 2μg used for cDNA synthesis (Omniscript 
RT kit, Qiagen). Quantitative PCR was carried out using specific primers and probes for 
rhinovirus (sense: 5’-GTG AAG AGC CSC RTG TGC T-3’ 50nM, antisense 5’-GCT SCA GGG 
TTA AGG TTA GCC-3’ 300nM, probe-5’-FAM-TGA GTC CTC CGG CCC CTG AAT G-
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TAMRA-3’ 175nM), interferon-λ1 (sense: 5’- GGA CGC CTT GGA AGA GTC ACT -3’ 
300nM, antisense: 5’- AGA AGC CTC AGG TCC CAA TTC -3’ 900nM, probe 5’-FAM AGT 
TGC AGC TCT CCT GTC TTC CCC G TAMRA-3’ 175nM), interferon- λ2/3 (sense: 5’- CTG 
CCA CAT AGC CCA GTT CA -3’ 300nM, antisense: 5’- AGA AGC GAC TCT TCT AAG 
GCA TCT T -3’  900nM, probe: 5’-FAM TCT CCA CAG GAG CTG CAG GCC TTT A 
TAMRA-3’ 175nM) and 18S rRNA  (sense: 5’- CGC CGC TAG AGG TGA AAT TCT -3’, 
antisense:  5’-  CAT TCT TGG CAA ATG CTT TCG-3’ 300nM each, probe: 5’-FAM ACC 
GGC GCA AGA CGG ACC AGA TAMRA-3’ 175nM). Reactions consisted of 2 μL of cDNA 
(cDNA for 18S was diluted 1:100), 12.5μL 2x QuantiTect Probe PCR Master Mix (Qiagen). 
Reactions were performed on an ABI 7000 TaqMan® (ABI Foster City CA), interferon-λ and 
viral RNA expression were normalised to 18S rRNA and compared to standard curves and 
expressed as copies per µg RNA.  
 
Peripheral blood mononuclear cells 
Peripheral blood mononuclear cells were obtained from whole blood from healthy volunteers by 
gradient centrifugation in lymphoprep (Histopaque 1077 – Sigma). They were washed and 
resuspended in RPMI-1640 medium with Glutamax (Life Technologies) containing 10% FCS and 
antibiotics (penicillin, streptomycin) at a final concentration of 2x106/mL in 6-well plates. 
Rhinovirus-16 was added at final a concentration of 5 MOI. After 1 hour of shaking at room 
temperature, cultures were placed in a humidified 5% CO2 incubator at 37°C. Supernatants were 
harvested at various time points, clarified by centrifugation, and stored at –80°C until assayed. 
Total RNA was extracted from cells using RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. This study was approved by St Mary’s NHS Trust Ethics Committee 
and all subjects gave informed consent. 
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Monocyte-derived macrophages 
Monocytes, isolated from peripheral blood mononuclear cells by positive selection using anti-
CD14 magnetic beads (MACS), were differentiated into monocyte derived macrophages by 
culture in 12-well plates for 7 days in macrophage serum-free-medium (M-SFM) (Invitrogen) 
supplemented with 10ng/mL GM-CSF (Biosource). Macrophages were exposed to rhinovirus-16 
at a MOI of 2 or UV inactivated virus with continuous shaking. After 1 hour cells were washed 
extensively and 1ml of M-SFM was added to each well. After 24 hours supernatants were 
harvested and stored at -80°C for analysis.  
 
Primary bronchial epithelial cell tissue culture 
Primary bronchial epithelial cells from 9 atopic asthmatic and 9 normal volunteers were obtained 
by fibreoptic bronchoscopy and cell culture was performed as previously described(1). Normal 
subjects had no history of respiratory disease, were non-atopic and had no bronchial 
hyperresponsiveness (PC20 histamine >8 mg/mL). Among the 9 asthmatic patients all were atopic 
(skin prick test positive) and with bronchial hyperresponsiveness (PC20 histamine <8 mg/mL), 2 
were steroid naïve and seven were on regular inhaled corticosteroids and 2 had mild intermittent, 
4 mild persistent, 2 moderate persistent and 1 severe persistent asthma according to international 
guidelines(1). Demographic details and clinical characteristics of included subjects are given in 
Table 1. All were non-smokers. Primary cultures were established by seeding freshly brushed 
bronchial epithelial cells into hormonally supplemented bronchial epithelial growth medium 
(BEGM; Clonetics, San Diego, USA) containing 50U/mL penicillin and 50μg/mL streptomycin. 
At passage 2 cells were seeded onto 12 well trays and cultured until 80% confluent(1)  before 
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exposure to rhinovirus-16 at an MOI of 2. Cell lysates were harvested after 8 hours incubation 
and total RNA extracted using RNeasy Mini Kit (Qiagen) according to manufacturer’s 
instructions. Supernatants were harvested at 48 hours post infection, clarified by centrifugation, 
and stored at –80°C until assayed. This study was approved by Southampton University Hospitals 
Ethics Committee and all subjects gave informed consent. 
 
Experimental rhinovirus infection of asthmatic and normal subjects 
Outline of experimental design 
Six atopic asthmatic and 8 non-atopic normal, rhinovirus-16 serum neutralising antibody negative 
subjects were recruited to this study, all were non smokers, demographic details and clinical 
characteristics are provided in Table 1.  All asthmatic and no normal subjects had bronchial 
hyperresponsiveness. Subjects underwent bronchoscopy with bronchoalveolar lavage at baseline 
and bronchoalveolar lavage cell pellets were incubated with rhinovirus-16 or bacterial LPS to 
determine interferon-λ production. Two weeks later, the same subjects underwent experimental 
rhinovirus inoculation. One asthmatic patient withdrew before experimental rhinovirus 
inoculation. Diary card recordings were performed daily from screening to 2 weeks after 
infection to document common cold symptoms. Daily spirometry was performed from screening 
to 2 weeks to document reductions in lung function measured as forced expiratory volume in 1 
second (FEV1). Bronchoalveolar lavage was repeated on day 4 after the acute infection and virus 
load determined by quantitative PCR. Subjects were free of common cold symptoms for 6 weeks 
before commencing the study. This study was approved by St Mary’s NHS Trust Ethics 
Committee and all subjects gave informed consent. Full details of the experimental design and 
validation of this human experimental model of acute exacerbations of asthma are described 
elsewhere ( SDM, manuscript in preparation). 
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Experimental infection with rhinovirus-16 
Experimental infection was induced using 10,000 tissue culture infective doses 50% (TCID50) of 
a safety tested rhinovirus-16 inoculum (49) by nasal spray, with a DeVillbiss 286 atomizer. 2 
aliquots of 500μL (each 2,500 TCID50) were applied to each nostril. Infection was confirmed by 
culture of post inoculation nasal lavage in Ohio HeLa cells and/or by positive serology (a four 
fold rise in neutralizing antibody titer between pre-inoculation sample and convalescent sample 
taken at 6 weeks post infection). Cultured viruses were confirmed as rhinovirus-16 by 
neutralisation of virus with rhinovirus-16 specific antiserum (ATCC).  
Recording of common cold symptoms 
A total common cold score for the 2 week period post virus inoculation was derived from diary 
card recordings maintained by the subject from screening. This score was corrected for baseline 
symptoms and for the effects of bronchoscopy. Symptoms recorded daily were sneezing, 
headache, malaise, chilliness, nasal discharge, nasal obstruction, sore throat, cough, fever, each 
graded 0-3 for absent, mild, moderate or severe.  
Lung Function Testing 
Subjects recorded daily morning FEV1 on a portable microDL spirometer (MicroMedical) at 
home from screening. Data was analysed using Spida software. Reductions in lung function were 
expressed as the maximum fall in FEV1 during the 2 weeks post virus inoculation expressed as 
the % change in FEV1 from the mean obtained during the baseline stage, corrected for the effects 
of bronchoscopy. Full details of the derivation of total cold scores and lung function assessment 
of this human experimental model of acute exacerbations of asthma are described elsewhere 
(SDM, manuscript in preparation). 
 
Bronchoscopy 
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Bronchoscopies were performed using a Keymed P100 bronchoscope. Bronchoalveolar lavage 
was performed by instillation of sterile normal saline (room temperature) into the right middle 
lobe bronchus in 8x30mL aliquots. Bronchoalveolar lavage was collected in a single plastic 
chamber and transferred immediately to polypropylene tubes on ice for transport to the laboratory 
for determination of rhinovirus virus load by quantitative PCR (as described above) in 
unprocessed lavage. One asthmatic volunteer recorded symptoms and lung function but did not 
have a successful bronchial lavage, so no virus load was determined for this subject. 
 
Bronchoalveolar lavage cell cultures 
Cells from the bronchoalveolar lavage obtained at baseline bronchoscopy were washed and 
resuspended in RPMI-1640 medium with Glutamax (Life Technologies, Uxbridge, UK) 
containing 10% FCS and antibiotics (penicillin, streptomycin), at a final concentration of 
2x106/mL. Cells were incubated with 5 MOI rhinovirus-16, with inoculum from which the virus 
had been removed by molecular weight filtration(10) or with 0.1µg/mL of E. Coli 026:B6 LPS 
(Sigma). After 48 hours supernatants were harvested and stored at -80°C for ELISA for 
interferon-λ. 
 
Statistical analysis 
Data for multiple comparisons were first analysed by ANOVA. If significant (p<0.05), 
differences between groups/conditions were then analysed using paired or unpaired t-tests as 
appropriate. Linear regression analysis was used when appropriate and the Pearson test to 
investigate correlations. All the analyses were performed using GraphPad Prism 4.0 for 
Windows. Data are expressed as mean and standard error of the mean. 
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Table 1. Demographic data for patients entering the clinical studies 
 Asthma Healthy controls p-value 
Primary bronchial epithelial cell study 
Number 9 9 NA 
Sex (percent male) 55.5 66.6 p=0.3 
Mean age (range) 31.2 (21-50) 27.8 (23-31) p=0.4 
Mean FEV1% predicted 
(SEM) 
84.1 (2.3) 108 (4.4) p<0.001 
Mean dose of ICSs, 
BDP µg/day (SEM) 
411.1 (118.4) 0 NA 
Experimental rhinovirus infection study 
Number 6 8 NA 
Sex (percent male) 16.7 50 p=0.2 
Mean age (range) 23.2 (19-31) 27.8 (23-31) p=0.5 
Mean FEV1% predicted 
(SEM) 
104.3 (3.9) 100.4 (7.1) p=0.6 
Histamine PC20 
mg/mL (SEM) 
3.1 (0.9) 13.9 (0.9) p<0.001 
FEV1: forced expiratory volume in 1 second 
SEM: standard error of the mean 
ICS: inhaled corticosteroids 
BDP: beclomethasone dipropionate equivalents 
PC20: provocative concentration causing a 20% fall in FEV1 
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replication dependent manner in both normal and asthmatic subjects. However levels of 
expression of both interferon-λ subtypes induced by infection were significantly lower in cells 
from asthmatic subjects. ***p<0.001 compared to medium control and UV-inactivated virus. 
###p<0.001 compared to normal subjects. 
(C) Rhinovirus induction of interferon-λ protein is strongly related to rhinovirus replication in 
primary bronchial epithelial cells. Levels of interferon-λ protein production induced by 
rhinovirus infection of primary bronchial epithelial cells was strongly inversely related (r2=0.46, 
p<0.01) to levels of viral RNA in the cell lysates from the same experiments. Red squares = 
asthmatic and white = normal subjects. 
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Interferon-λ protein production in bronchoalveolar lavage cells infected in vitro with rhinovirus-
16, was significantly inversely correlated with bronchoalveolar lavage virus load determined on 
day 4 of the acute infection period when subjects were subsequently experimentally infected with 
rhinovirus-16 in vivo (r2 0.44, p<0.05). Red squares = asthmatic and White = normal subjects. 
(C) Rhinovirus induction of interferon-λ protein by bronchoalveolar lavage cells is strongly 
related to severity of reduction in lung function on subsequent in vivo rhinovirus experimental 
infection. Interferon-λ protein production in bronchoalveolar lavage cells infected in vitro with 
rhinovirus-16, was significantly inversely correlated with severity of maximal reduction from 
baseline in FEV1 recorded over the 2 weeks infection period when subjects were subsequently 
experimentally infected with rhinovirus-16 in vivo (r2 0.43, p<0.05). Red squares = asthmatic and 
White = normal subjects. 
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Figure 5 Deficient LPS induced interferon-λ production from bronchoalveolar lavage cells 
from asthmatic compared to normal subjects and relationship to lung function in vivo 
(a) LPS induces interferon-λ protein production in bronchoalveolar lavage cells and induction is 
deficient in asthmatic compared to normal subjects. Bronchoalveolar lavage cells from asthmatic 
and normal subjects were stimulated with LPS or medium control (M) and interferon-λ protein 
production determined in supernatants by ELISA at 48 hours after infection. Production of 
interferon-λ was significantly increased in cells stimulated with LPS in both normal and 
asthmatic subjects. However production of interferon-λ induced by LPS was significantly lower 
in cells from asthmatic subjects. ***p<0.001 and **p<0.01 compared to medium control. 
#p<0.05 compared to normal subjects. 
(b) LPS induction of interferon-λ protein in bronchoalveolar lavage cells is strongly related to 
severity of reduction in lung function on subsequent in vivo rhinovirus experimental infection. 
Interferon-λ protein production in bronchoalveolar lavage cells stimulated in vitro with LPS, was 
significantly inversely correlated with severity of maximal reduction from baseline in FEV1 
recorded over the 2 weeks infection period when subjects were subsequently experimentally 
infected with rhinovirus-16 in vivo (r2 0.40, p<0.05). Red squares = asthmatic and White = 
normal subjects. 
 
 
 
 
 
 
  
91 
 
References 
1. Wark P, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, Holgate ST, 
Davies DE. Asthmatic bronchial epithelial cells have a deficient innate immune response to 
infection with rhinovirus. J Exp Med 2005;201:937-947. 
2. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, 
Sheikh F, Dickensheets H, Donnelly RP. Ifn-lambdas mediate antiviral protection through a 
distinct class ii cytokine receptor complex. Nat Immunol 2003;4:69-77. 
3. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, 
Kuestner R, Garrigues U, Birks C, Roraback J, et al. Il-28, il-29 and their class ii cytokine 
receptor il-28r. Nat Immunol 2003;4:63-68. 
4. Bartlett NW, Buttigieg K, Kotenko SV, Smith GL. Murine interferon lambdas (type iii 
interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen Virol 
2005;86:1589-1596. 
5. Greve JM, Davis G, Meyer AM, Forte CP, Yost SC, Marlor CW, Kamarck ME, 
McClelland A. The major human rhinovirus receptor is icam-1. Cell 1989;56:839-847. 
6. Hofer F, Gruenberger M, Kowalski H, Machat H, Huettinger M, Kuechler E, Blass D. 
Members of the low density lipoprotein receptor family mediate cell entry of a minor-group 
common cold virus. Proc Natl Acad Sci U S A 1994;91:1839-1842. 
7. Barchet W, Cella M, Odermatt B, Asselin-Paturel C, Colonna M, Kalinke U. Virus-
induced interferon alpha production by a dendritic cell subset in the absence of feedback 
signaling in vivo. J Exp Med 2002;195:507-516. 
8. Huguenel ED, Cohn D, Dockum DP, Greve JM, Fournel MA, Hammond L, Irwin R, 
Mahoney J, McClelland A, Muchmore E, et al. Prevention of rhinovirus infection in chimpanzees 
by soluble intercellular adhesion molecule-1. Am J Respir Crit Care Med 1997;155:1206-1210. 
  
92 
 
9. Lomax NB, Yin FH. Evidence for the role of the p2 protein of human rhinovirus in its 
host range change. J Virol 1989;63:2396-2399. 
10. Papi A, Johnston SL. Rhinovirus infection induces expression of its own receptor 
intercellular adhesion molecule 1 (icam-1) via increased nf-kappab-mediated transcription. J Biol 
Chem 1999;274:9707-9720. 
11. Talbot TR, Hartert TV, Mitchel E, Halasa NB, Arbogast PG, Poehling KA, Schaffner W, 
Craig AS, Griffin MR. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 
2005;352:2082-2090. 
12. Hewson CA, Jardine A, Edwards MR, Laza-Stanca V, Johnston SL. Toll-like receptor 3 is 
induced by and mediates antiviral activity against rhinovirus infection of human bronchial 
epithelial cells. J Virol 2005;79:12273-12279. 
13. Tissari J, Siren J, Meri S, Julkunen I, Matikainen S. Ifn-{alpha} enhances tlr3-mediated 
antiviral cytokine expression in human endothelial and epithelial cells by up-regulating tlr3 
expression. J Immunol 2005;174:4289-4294. 
14. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha 
PM, Golenbock DT. Lps-tlr4 signaling to irf-3/7 and nf-kappab involves the toll adapters tram 
and trif. J Exp Med 2003;198:1043-1055. 
15. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. 
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and 
corticosteroids establishing therapy (facet) international study group. N Engl J Med 
1997;337:1405-1411. 
16. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, Weiss ST. 
Worldwide severity and control of asthma in children and adults: The global asthma insights and 
reality surveys. J Allergy Clin Immunol 2004;114:40-47. 
  
93 
 
17. Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled 
corticosteroid to prevent asthma exacerbations: Randomised controlled trial. Lancet 
2004;363:271-275. 
18. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, Symington P, 
O'Toole S, Myint SH, Tyrrell DA, et al. Community study of role of viral infections in 
exacerbations of asthma in 9-11 year old children. BMJ 1995;310:1225-1229. 
19. Chauhan AJ, Johnston SL. Air pollution and infection in respiratory illness. Br Med Bull 
2003;68:95-112. 
20. Corne JM, Marshall C, Smith S, Schreiber J, Sanderson G, Holgate ST, Johnston SL. 
Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic 
individuals: A longitudinal cohort study. Lancet 2002;359:831-834. 
21. Gern JE, Busse WW. Relationship of viral infections to wheezing illnesses and asthma. 
Nat Rev Immunol 2002;2:132-138. 
22. Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. Suppression of the induction of alpha, 
beta, and lambda interferons by the ns1 and ns2 proteins of human respiratory syncytial virus in 
human epithelial cells and macrophages [corrected]. J Virol 2004;78:4363-4369. 
23. Spurrell JC, Wiehler S, Zaheer RS, Sanders SP, Proud D. Human airway epithelial cells 
produce ip-10 (cxcl10) in vitro and in vivo upon rhinovirus infection. Am J Physiol Lung Cell 
Mol Physiol 2005;289:L85-95. 
24. Schroth MK, Grimm E, Frindt P, Galagan DM, Konno SI, Love R, Gern JE. Rhinovirus 
replication causes rantes production in primary bronchial epithelial cells. Am J Respir Cell Mol 
Biol 1999;20:1220-1228. 
  
94 
 
25. Papadopoulos NG, Bates PJ, Bardin PG, Papi A, Leir SH, Fraenkel DJ, Meyer J, Lackie 
PM, Sanderson G, Holgate ST, et al. Rhinoviruses infect the lower airways. J Infect Dis 
2000;181:1875-1884. 
26. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded rna 
and activation of nf-kappab by toll-like receptor 3. Nature 2001;413:732–738. 
27. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, Mudd S, Shamel L, Sovath S, 
Goode J, et al. Toll-like receptors 9 and 3 as essential components of innate immune defense 
against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A 2004;101:3516-3521. 
28. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L, Azuma YT, 
Flavell RA, Liljestrom P, Reis e Sousa C. Toll-like receptor 3 promotes cross-priming to virus-
infected cells. Nature 2005;433:887-892. 
29. Melchjorsen J, Jensen SB, Malmgaard L, Rasmussen SB, Weber F, Bowie AG, 
Matikainen S, Paludan SR. Activation of innate defense against a paramyxovirus is mediated by 
rig-i and tlr7 and tlr8 in a cell-type-specific manner. J Virol 2005;79:12944-12951. 
30. Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, Casrouge A, Picard C, von Bernuth H, 
Senechal B, Plancoulaine S, et al. Human tlr-7-, -8-, and -9-mediated induction of ifn-alpha/beta 
and -lambda is irak-4 dependent and redundant for protective immunity to viruses. Immunity 
2005;23:465-478. 
31. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, 
Wagner H, Bauer S. Species-specific recognition of single-stranded rna via toll-like receptor 7 
and 8. Science 2004;303:1526-1529. 
32. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, 
Takeda K, Akira S. Small anti-viral compounds activate immune cells via the tlr7 myd88-
dependent signaling pathway. Nat Immunol 2002;3:196-200. 
  
95 
 
33. Hochrein H, Schlatter B, O'Keeffe M, Wagner C, Schmitz F, Schiemann M, Bauer S, 
Suter M, Wagner H. Herpes simplex virus type-1 induces ifn-alpha production via toll-like 
receptor 9-dependent and -independent pathways. Proc Natl Acad Sci U S A 2004;101:11416-
11421. 
34. Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK, Archer DR, Barber GN. 
Essential role for the dsrna-dependent protein kinase pkr in innate immunity to viral infection. 
Immunity 2000;13:129-141. 
35. Leib DA, Machalek MA, Williams BR, Silverman RH, Virgin HW. Specific phenotypic 
restoration of an attenuated virus by knockout of a host resistance gene. Proc Natl Acad Sci U S 
A 2000;97:6097-6101. 
36. Carr DJ, Tomanek L, Silverman RH, Campbell IL, Williams BR. Rna-dependent protein 
kinase is required for alpha-1 interferon transgene-induced resistance to genital herpes simplex 
virus type 2. J Virol 2005;79:9341-9345. 
37. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, 
Akira S, Fujita T. The rna helicase rig-i has an essential function in double-stranded rna-induced 
innate antiviral responses. Nat Immunol 2004;5:730-737. 
38. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda 
K, Fujita T, Takeuchi O, et al. Cell type-specific involvement of rig-i in antiviral response. 
Immunity 2005;23:19-28. 
39. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva 
M, Galanos C, et al. Defective lps signaling in c3h/hej and c57bl/10sccr mice: Mutations in tlr4 
gene. Science 1998;282:2085-2088. 
  
96 
 
40. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, 
Schwartz DA. Tlr4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat 
Genet 2000;25:187-191. 
41. Hacker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, Wang GG, Kamps MP, Raz 
E, Wagner H, Hacker G, et al. Specificity in toll-like receptor signalling through distinct effector 
functions of traf3 and traf6. Nature 2006;439:204-207. 
42. Oganesyan G, Saha SK, Guo B, He JQ, Shahangian A, Zarnegar B, Perry A, Cheng G. 
Critical role of traf3 in the toll-like receptor-dependent and -independent antiviral response. 
Nature 2006;439:208-211. 
43. Thanos D, Maniatis T. The high mobility group protein hmg i(y) is required for nf-kappa 
b-dependent virus induction of the human ifn-beta gene. Cell 1992;71:777-789. 
44. Du W, Maniatis T. An atf/creb binding site is required for virus induction of the human 
interferon beta gene [corrected]. Proc Natl Acad Sci U S A 1992;89:2150-2154. 
45. Falvo JV, Parekh BS, Lin CH, Fraenkel E, Maniatis T. Assembly of a functional beta 
interferon enhanceosome is dependent on atf-2-c-jun heterodimer orientation. Mol Cell Biol 
2000;20:4814-4825. 
46. Illi S, von Mutius E, Lau S, Bergmann R, Niggemann B, Sommerfeld C, Wahn U. Early 
childhood infectious diseases and the development of asthma up to school age: A birth cohort 
study. BMJ 2001;322:390-395. 
47. Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M, Grize L, Maisch S, Carr D, 
Gerlach F, Bufe A, et al. Environmental exposure to endotoxin and its relation to asthma in 
school-age children. N Engl J Med 2002;347:869-877. 
48. Kaur B, Anderson HR, Austin J, Burr M, Harkins LS, Strachan DP, Warner JO. 
Prevalence of asthma symptoms, diagnosis, and treatment in 12-14 year old children across great 
  
97 
 
britain (international study of asthma and allergies in childhood, isaac uk). BMJ 1998;316:118-
124. 
49. Bardin PG, Sanderson G, Robinson BS, Holgate ST, Tyrrell DA. Experimental rhinovirus 
infection in volunteers. Eur Respir J 1996;9:2250-2255. 
 
  
  
98 
 
Respiratory virus production of alpha-, beta- and lambda-interferons in bronchial 
epithelial cells: comparison of patterns of induction 
 
M. R. Khaitov1,2, M. R. Edwards1, R. P. Walton1, G. Rohde1,3, M. Contoli1,4, L. A. Stanciu1, S. 
V. Kotenko3,5, S. L. Johnston1 
 
1Department of Respiratory Medicine, National Heart and Lung Institute, Wright Fleming 
Institute of Infection and Immunity and MRC and Asthma UK Centre in Allergic Mechanisms of 
Asthma, Imperial College London, Norfolk Place, London, UK;  
2State National Center Institute of Immunology Federal Medicobiological Agency of Russia, 
Moscow, Russia; 
3Department of Internal Medicine III, Pneumology, Allergology and Sleep Medicine, University 
Hospital Bergmannsheil, Bochum, Germany 
4Research Centre on Asthma and COPD, University of Ferrara, Ferrara, Italy 
5Department of Biochemistry & Molecular Biology, University of Medicine and Dentistry New 
Jersey – New Jersey Medical School, Newark, NJ, USA 
 
  
  
99 
 
Background and Aims  
Respiratory viruses, are the major cause of asthma exacerbations. Impaired production of 
interferon-β and of interferon-λs is implicated in asthma exacerbation pathogenesis. Thus 
replacement of deficient interferon is a candidate new therapy for asthma exacerbations. 
Rhinoviruses and other respiratory viruses infect bronchial epithelial cells (BECs), but their 
relative capacities for α-, β- and λ-interferon production are unknown.  
Aim: To provide guidance regarding which interferon type is the best candidate for development 
for treatment/prevention of asthma exacerbations we investigated respiratory virus induction of 
α-, β- and λ-interferon in BECs by reverse transferase-polymerase chain reaction and enzyme-
linked immunosorbent assay (ELISA). 
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 Asthmatic individuals are more susceptible to naturally occurring rhinovirus (RV) infection than 
normal individuals (1)  and it has been recently reported that primary bronchial epithelial cells 
(BECs) from asthmatic subjects exposed to RV in vitro had profoundly impaired production of 
interferon (IFN)-β compared to normal bronchial epithelial cells (2) . In these studies, normal 
BECs were almost completely resistant to RV infection, and impaired IFN-β production in 
asthmatic cells was strongly correlated with increased RV replication. Restoring IFN-β responses 
with exogenous IFN-β in asthmatic cells restored antiviral activity and rendered asthmatic cells 
as resistant to infection as normal ones (2) . These studies suggest IFN-β could be an effective 
therapy for RV-induced asthma exacerbations. We have recently demonstrated that type III IFN-
λs are also produced by human BECs on infection with RV and are antiviral against RVs in vitro 
(3) . Further, they are also produced by RV-infected bronchoalveolar lavage (BAL) cells (~90% 
macrophages) and production by both BAL cells and BECs was deficient in asthmatic compared 
to normal subjects (3) . Importantly, IFN-λ production was strongly inversely correlated with 
severity of clinical illness, and with virus load and airway inflammation, when subjects were 
experimentally infected with RV in vivo (3) . These data strongly implicate type III IFN 
deficiency in the pathogenesis of asthma exacerbations. 
These studies combined suggest that administration of IFN-β or IFN-λs, is likely to be an 
attractive approach to prevention and/or therapy of virus induced asthma exacerbations. 
However, little is known about the types of IFNs produced by virus infected BECs, nor about the 
relative contributions of the different types of IFNs in response to rhinoviruses. We have recently 
shown that BECs induces both IFN-β (2) and IFN-λ (3) . 
We have therefore investigated respiratory virus induction of type I and type III IFNs in the 
BEAS-2B BEC line and in primary BECs. We elected to study RVs as the most common virus 
type implicated in asthma exacerbations, and influenza virus type A as a respiratory virus known 
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to suppress type I IFN responses, as the patterns of induction could be different for this virus 
type.  
 
Materials and methods 
 
Primary BECs and BEAS-2B tissue culture 
All cells were cultured at 37°C in 5% CO2. Primary BECs obtained from three different donors 
were purchased from Cambrex, USA. Primary cultures were established by seeding bronchial 
epithelial cells into supplemented bronchial epithelial growth medium (BEBM) according to the 
manufacturer_s instructions (Cambrex). Cells were seeded onto 12 well trays and cultured until 
80% confluent before exposure to virus. The human bronchial epithelial cell line BEAS-2B 
(ECACC) was cultured in RPMI-1640 supplemented with 10% FCS (Invitrogen). BEAS-2B cells 
were cultured in 12-well tissue culture plates (Nalge Nunc) for 24-h before being placed into 2% 
FCS RPMI medium for a further 24-h prior to infection. 
 
Viral stocks 
Rhinovirus serotypes 16 and 1B obtained from the Medical Research Council Common Cold 
Unit were grown in Ohio HeLa cells and prepared as previously described (4) . Viral stocks were 
used at 1 · 107 TCID50/ml. The identities of all RVs were confirmed by titration on HeLa cells 
and neutralization using serotype-specific antibodies (ATCC). Ultraviolet (UV) inactivation was 
performed as previously described (5) . Influenza A Victoria 75/3 (gift from Peter Morley, GSK, 
Stevenage) was propagated in MDCK cell cultures (gift from Peter Morley). At 80% confluence 
cell cultures were washed twice with sterile PBS and then growth medium replaced with serum 
free eagle minimum essential medium (Invitrogen). 0.5 ml of influenza stock was added to each 
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flask and incubated for 1 h. Cells were then washed to remove any non-adherent virus and 
resuspended in serum free medium for culture for 48 hours. Two days after infection, 
supernatants were collected from flasks, aliquotted and stored at -80°C for future use. Viruses 
were titrated on MDCK cells to determine TCID50/ml. Stock was assessed as being at 107 
TCID50/ml.  
 
Infection of cells with RV and influenza virus 
BEAS-2B cells were seeded in 12 well plates (Nunc, Roskilde, Denmark) at 1.7 · 105 cells/ml, 
allowed to attach and grow for 24 h. BEAS-2B were then placed in RPM1 1640 + 2% FCS 
(infection media) overnight. Cells were then treated with RV16 or RV1B [multiplicity of 
infection (MOI) of 1] for 1 h at room temperature with shaking. Cells supernatants and RNA 
lysates were harvested at the times indicated. Supernatants and lysates were stored at -80°C until 
required. The same protocol was used for infecting cells with Influenza A Victoria 75/3 virus. 
Virus was used at a MOI of 1. 
 
RNA extraction, reverse transcription and TaqMan  real-time PCR 
RNA was extracted from cells using the RNeasy method (RNeasy Mini Kit; Qiagen) following 
the manufacturer_s instructions, including the optional DNaseI digestion of contaminating DNA 
(Dnase (Rnase free Dnase); Qiagen). cDNA was synthesized using Omniscript RT and 
components as directed by the manufacturer (Qiagen). Primers specific for IFN-αs, IFN-β, IFN-
λ1, IFN-λ2/3 were purchased from Invitrogen and probes from Qiagen (Table 1). TaqMan 
analysis of -α, -β and -λ interferon mRNA was normalized with respect to 18s rRNA and 
presented as log10-fold induction relative to medium control. Reactions consisted of 12.5 µl 2 x 
QuantiTect Probe PCR Master Mix (Qiagen) and 300 nM of forward primer and 900 nM of 
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reverse primer for IFN-α.1, 300 nM of each primer for IFN-α.2, 300 nM and 900 nM for IFN-β, 
IFN-λ1 and IFN-λ2/3, 300 nM of each primer for 18s; 175 nM of each specified probe was used. 
Two microliters of cDNA (18s diluted 1/100) was made up to 25 ll with nuclease-free water 
(Promega). The reactions were analysed using an ABI7000 Automated TaqMan (Applied 
Biosystems). The amplification cycle consisted of 50°C for 2 min, 94°C for 10 min and 40 cycles 
of 94°C for 15 s, 60°C for 15 s. 
 
Enzyme-linked immunosorbent assay to evaluate IFN-α, IFN-β and IFN-λ  
Interferon-α and IFN-β proteins were quantified by enzyme-linked immunosorbent assay 
(ELISA) in supernatants from untreated and infected cell cultures collected and stored at -80°C 
using commercially available paired antibodies and standards, following the manufacturer’s 
instructions using a high sensitivity IFN-α human Biotrak ELISA (Amersham Biosciences), and a 
human IFN-β ELISA kit (Biosource). All the measurements were done according to 
manufacturer‘s instructions. The detection limits for described assays are 0.63 pg/ml for IFN-α, 
2.5 pg/ml for IFN-β. To measure interferon-λs we developed an assay using a monoclonal anti-
human IL-29/IFN-λ1 antibody as capture, a polyclonal anti-IL-29 antibody as secondary and 
biotin conjugated donkey anti-goat IgG as third antibody (all R&D Systems) followed by 
streptavidin conjugated HRP (Biosource). Recombinant human IL-29 (Peprotech) was used as 
standard. The sensitivity of the assay was 25 pg/ml. The assay for IFN-lambda detection detects 
IL-29 protein but also detects some IL-28 as there is 25% cross-reactivity with IL-28. 
 
Statistical analysis 
Data are presented as mean (SEM). For time course experiments data were analysed using one-
way anova for repeated measures followed by paired t-tests between baseline and individual time 
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points where appropriate. For other comparisons paired t-tests and Bonferroni’s multiple 
comparison post hoc test were used. Data were accepted as significantly different when p<0.05. 
 
Results 
 
Rhinovirus induction of type I and type III interferons in BEAS-2B BECs  
The time course of expression of type I and type III IFN mRNAs was studied during infection of 
BEAS-2B cells with RV-16. There was no significant induction by RV-16 of IFN-α subtypes 1, 6 
or 13 detected by IFN-α.1 at either 4, 8 or 24 h, however, subtypes 2, 4, 5, 8, 10, 14, 17 and/or 
21, detected by IFN-α.2, were significantly induced in comparison to medium at 8 h [2.74 (0.3) 
log10-fold induction compared to medium, P < 0.001], but not at 4 or 24 h . IFN-β mRNA 
expression was induced by RV-16 only at 24 h [3.22 (0.33), P < 0.001], while IFN-λ1 mRNA 
expression was statistically significantly increased by RV-16 at 8 h [3.1 (0.75), P < 0.01] and 
further increased at 24 h [4.84 (0.24), P < 0.001]. We next investigated whether the induction of 
IFN mRNAs by RV-16 infection of BEAS-2B cells leads to production of detectable levels of 
type I and type III IFN proteins at 24 h after infection. We detected no significant induction of 
IFN-α protein, but IFN-β protein production was significantly increased [19.8 (2.3) pg/ml, P < 
0.01, Fig. 1C] while IFN-λ was produced at greater levels [99.89 (2.03) pg/ml, P < 0.001, Fig. 
1D] in RV-16 infected BEAS-2B cells in comparison to non-infected cells. 
 
Rhinovirus induction of type I and type III interferons in primary BECs. 
Similar to BEAS-2B cells, there was no significant induction by RV-16 of IFN-α subtypes 
detected by IFN-α.1 at 4, 8 or 24 h, however, subtypes detected by IFN-α.2 were significantly 
induced in comparison to medium at 8 h [3.06 (0.24) log10-fold induction compared to medium, 
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P < 0.001] and remained elevated at 24 h, though at 24 h this was not statistically significant. 
Also similar to BEAS-2B cells, IFN-β mRNA expression was induced by RV-16 only at 24 h 
[4.1 (0.44), P < 0.001]. IFN-λ2/3 mRNA expression paralleled the increase in IFN-λ1, both being 
induced by RV-16 at 8 h [IFN-λ2/3 2.75 (0.23), P < 0.001 and IFN-λ1 2.2 (1.23), P = NS] and 
further induced at 24 h [IFN-λ2/3 4.2 (0.12), and IFN-λ1 5.03 (0.21), both P < 0.001]. These 
levels of mRNA induction were not sufficient to lead to production of detectable levels of type I 
and type III IFN proteins at 24 h after infection, as each of α, β, and λ IFNs were undetectable.  
 
Rhinovirus induction of type I and type III interferons in primary BECs is receptor independent 
and replication dependent 
To determine whether RV induction of type I and type III IFNs in primary BECs is receptor 
restricted or not we next investigated the effect of RV-1B. Similar to RV-16, there was no 
significant induction by RV-1B of IFN-α subtypes detected by IFN-α.1 at 4, 8 or 24 h, however, 
subtypes detected by IFN-α.2 were significantly induced in comparison to medium at 8 h [2.96 
(0.29) log10-fold induction compared to medium] though these remained significantly elevated at 
24 h [3.1 (0.4), both P < 0.05]. Also similar to RV-16, IFN-β mRNA expression was induced by 
RV-1B only at 24 h [4.12 (0.25), P < 0.01]. IFN-λ2/3 mRNA expression again paralleled the 
increase in IFN-λ1, both being induced by RV-1B at 8 h [IFN-λ2/3 3.76 (0.19), P < 0.05 and 
IFN-λ1 1.83 (0.65), P = NS] remaining induced at 24 h [IFN-λ2/3 3.6 (0.2) P < 0.05, and IFN-λ1 
5.01 (0.38), P < 0.001,]. Again, these levels of mRNA induction were not sufficient to lead to 
production of detectable levels of type I and type III IFN proteins at 24 h after infection. We next 
investigated the effects of live and UV-inactivated RV-16 to determine whether IFN induction 
was replication dependent. In these experiments UV-inactivated RV-16 induced no type I or type 
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III IFN mRNA , indicating that RV-induced expression of type I and type III IFNs has a 
replication dependent mechanism.  
 
Influenza virus induction of type I and type III interferons in primary BECs 
Influenza viruses are important respiratory pathogens also implicated in asthma exacerbations (6, 
7) , they are also known to suppress type I IFN responses (8-11). We therefore next investigated 
the effects of influenza virus type A on type I and type III IFNs in primary BECs. Similar to RV 
induction, there was no significant induction by influenza virus of IFN-α subtypes detected by 
IFN-α.1 at 4, 8 or 24 h, however, subtypes detected by IFN-α.2 were significantly induced in 
comparison to medium at 24 h [2.46 (0.16) log10-fold induction compared to medium, P < 0.01] 
though not at earlier time points. Also similar to RV induction, IFN-β mRNA expression was 
induced by influenza virus only at 24 h [4.16 (0.14), P < 0.001] and IFN-λ2/3 mRNA expression 
again paralleled the increase in IFN-λ1, both being induced by influenza virus at 8 h [IFN-λ2/3 
3.48 (0.04), and IFN-λ1 3.13 (0.36), both P < 0.001] and remaining elevated at 24 h [IFN-λ2/3 
3.84 (0.17) P < 0.001, and IFN-λ1 4.97 (0.09), P = NS]. Again, all  IFN proteins were 
undetectable at 24 h in influenza virus infected primary BECs.  
 
Discussion 
 
Here we show that the BEC line BEAS-2B and primary BECs expressed increased levels of 
mRNAs of α, β, and λ-IFNs in response to RV infection, but that λ-IFNs were the most strongly 
induced both early and during sustained induction (Figure 1). RV induction of IFN proteins were 
mostly below detection limits, but when proteins were detected in BEAS-2B cells, IFN-λs were 
detected at the highest levels. Similar results were obtained with influenza A virus infection of 
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primary BECs (Figure 2). Respiratory epithelial cells are the major site of RV replication as 
replication has been confirmed in both BEC lines (4, 5)  and primary BECs (2, 3, 12)  in vitro, 
and RV has been detected by in situ hybridization and immunochemistry within the BEC cell 
layer in bronchial biopsies in vivo. BEC innate responses to RV infection are therefore likely of 
major importance in protection against RV infections. This interpretation is supported by the 
recent evidence implicating impaired BEC innate responses in the pathogenesis of rhinovirus 
induced asthma exacerbations (2, 3) . Our studies indicate both in a cell line and in primary cells, 
that IFN-λs are likely the most abundant IFN type induced in response to RV infection of BECs. 
These data would support the development of IFN-λs as candidate therapy for asthma 
exacerbations, as well as perhaps other viral diseases where BECs are the major site of virus 
replication. We were unable to detect IFN proteins at 24 h in RV infected primary BECs. Both 
IFN-α and IFN-β mRNAs were expressed only at low levels (~3–4 logs), protein levels may thus 
have been below the detection limits of the assays. We believe that the levels of induction of IFN 
mRNA in BEAS2B cells or primary BECs were not sufficient to generate detectable levels of 
protein production using the assays available. For both α and β-IFNs it is likely that IFN proteins 
are quickly taken up by the IFN-αb receptor as the affinity of the IFN AR2 subunit for IFN-α2 
alone is high and increased up to 20-fold when complexed with IFN AR1 (13). The affinities of 
the IFN-λ receptor subunits for the IFN-λs are not known and the assay for IFN-λs was 
considerably less sensitive (25 pg/ml) than those for type I IFNs (0.63 and 2.5 pg/ml for a and b, 
respectively), potentially explaining why the IFN-λs were not detectable despite mRNAs being 
induced to higher levels than the type I IFNs.  
Our data indicate that in the context of RV infection of their natural lower respiratory tract host 
cells (BECs), induction of IFN-λs is likely important in both early induction events, as well as 
sustained induction consequent upon autocrine/paracrine signalling, however, further studies on 
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RV infection in BECs and the interplay between type I and type III IFNs will be required to 
dissect these relationships further. We also investigated influenza virus type A induction of IFNs 
in primary BECs as this virus type is known to suppress type I IFN production via its NS1 protein 
(8-11) and influenza induction may therefore differ from RV. The pattern of IFN-λ responses 
observed with influenza infection of BECs was similar to that observed with RV. However 
induction of IFN-α was different, as there was no early induction - both IFN-β and subtypes of 
IFN-α detected by primer/probe IFN-α.2 were only induced late at 24 h. It is likely the lack of an 
early IFN-αβ response is a consequence of the known action of influenza NS1 in suppressing 
type I IFN production (8-11). Influenza virus suppresses type I IFN production by inhibition of 
the transcription factors NF-κB (11, 13-15) and IRF3 (10) which are essential for activation of αβ 
IFN promoters. Influenza virus is also thought to inhibit type I IFN production by inhibiting 
double-stranded-RNA (dsRNA)-activated protein kinase (PKR) (8). The early induction of IFN-
λs by influenza suggests these IFNs may be less susceptible to the same mechanisms of viral 
suppression of IFN induction. Further work will be needed to investigate these possibilities.  
We conclude that both type I and type III IFNs are induced by RV and influenza infection of 
BECs, but IFN-λs appear to be the principal IFNs involved in responses to respiratory viruses in 
BECs. 
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Table 1 
Primer and probe set  Subtypes detected Sequence of primers and probes References 
IFN-α1 1,6,13 Forward – 5’-CAG AGT CAC CCA TCT CAG CA-3’ 
Reverse – 5’-CAC CAC CAG GAC CAT CAG TA-3’ 
Probe – 5’-FAM ATC TGC AAT ATC TAC GAT GGC CTC GCC TAMRA-3’ 
25 
IFN-α2 2, 4, 5, 8, 10, 14, 
17, 21 
Forward – 5’-CTG GCA CAA ATG GGA AGA AT-3’ 
Reverse – 5’-CTT GAG CCT TCT GGA ACT GG-3’ 
Probe – 5’-FAM TTT CTC CTG CCT GAA GGA CAG ACA TGA TAMRA-
3’ 
25 
IFN-β IFN-β Forward – 5’-CGC CGC ATT GAC CAT CTA-3’ 
Reverse – 5’-GAC ATT AGC CAG GAG GTT CTC A-3’ 
Probe – 5’-FAM TCA GAC AAG ATT CAT CTA GCA CTG GCT GGA 
TAMRA -3’ 
14 
IFN-λ1 IL-29 Forward – 5’-GGA CGC CTT GGA AGA GTC ACT-3’ 
Reverse – 5’-AGA AGC CTC AGG TCC CAA TTC-3’ 
Probe – 5’-FAM AGT TGC AGC TCT CCT GTC TTC CCC G TAMRA-3’ 
19 
IFN-λ2/3 IL-28A/B Forward – 5’-CTG CCA CAT AGCCCA GTT CA-3’ 
Reverse – 5’-AGA AGC GAC TCT TCT AAG GCA TCT T-3’ 
Probe – 5’-FAM TCT CCA CAG GAG CTG CAG GCC TTT A TAMRA-3’ 
19 
18S 18S Forward – 5’-CGC CGC TAG AGG TGA AAT TCT-3’ 
Reverse – 5’-CAT TCT TGG CAA ATG CTT TCG-3’ 
Probe – 5’-FAM ACC GGC GCA AGA CGG ACC AGA TAMRA-3’ 
37 
 
Table 1. Sequences of primers and probes used for detection of IFN-α, IFN-β, IL-29, IL-28A/B 
and 18S 
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Figure 1 
 
 
 
 
Figure 1. Time course of RV-16 induction of type I and type III IFNs in primary BECs. The 
expression of IFN mRNAs was assessed by Taqman PCR. IFN-αs detected by IFN-α.1 primer 
pair were not induced by rhinovirus 16. With IFN-α.2 statistically significant induction was 
observed by 8 h (n = 4, P < 0.01 compared to time point 0). Significant induction of IFN-β 
mRNA by RV-16 was detected only at 24 h (n = 4, P < 0.001 compared to time point 0). IFN-
λ1mRNA expression was up-regulated at 8 and 24 h (n = 4, P < 0.01 and P < 0.001 respectively 
compared to time point 0).  
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Figure 2 
 
 
Figure 2. Time course of influenza virus induction of type I and type III IFNs in primary BECs. 
The expression of IFN mRNAs was assessed by Taqman PCR. IFN-α subtypes detected by 
primer/probe IFN- α.1 were not induced by rhinovirus 16. IFN- α.2 primer/probe detected 
significant induction at 24 h (n = 4, P < 0.01 compared to time point 0). Significant induction of 
IFN-β mRNA by influenza virus was detected at 24 h (n = 6, P < 0.001 compared to time point 
0). IFN-λ1 mRNA was significantly induced by influenza virus at 8 h (n = 4, P < 0.001 compared 
to time point 0) and 24 h (n = 4, P < 0.001 compared to time point 0).  
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Background and Aims 
 
 
Rhinoviruses are believed to directly infect airway epithelium inducing pro-inflammatory 
cytokine production (1-3). This leads to recruitment and activation of inflammatory cells, 
resulting in airway inflammation (4, 5).  
Increased oxidative stress is implicated in induction of the acute airway inflammation during 
exacerbations of asthma and COPD (6). Oxidants are directly involved in inflammatory 
responses via signaling mechanisms, including the redox-sensitive activation of transcription 
factors such as NF-kB (7, 8).  
Recent data indicate that rhinovirus and other respiratory viruses can alter cellular redox 
homeostatic balance towards a pro-oxidative condition (9-11). The molecular pathways 
responsible for such disequilibrium are virtually unknown. In a previous study we documented 
that rhinovirus infection induces a rapid increase of intracellular superoxide anion (O2-), which 
occurs within 15 min after infection. This early pro-oxidative response was found to induce NF-
kB activation and downstream pro-inflammatory molecule production (12).  
O2- is a product of cellular metabolism and mainly originates from the activity of two enzyme 
systems: NADPH oxidase and xanthine dehydrogenase/xanthine oxidase (XD/XO) (13).  
Here we studied the molecular mechanisms by which rhinovirus induces rapid O2- production in 
respiratory epithelial cells. We also analyzed the mechanisms by which reducing agents can 
abolish rhinovirus induced O2- production and thus can stabilize the intracellular redox state in 
respiratory epithelial cells following infection. Finally, we demonstrated that blocking the 
activity of the system responsible for rhinovirus triggered O2- generation inhibited rhinovirus 
induced inflammatory mediator production in respiratory epithelial cells.   
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Experimental procedures 
 
Cell culture- Ohio HeLa cells were obtained from the MRC Common Cold Unit, Salisbury, UK, 
and A549 cells, a type II respiratory cell line, were obtained from the American Type Culture 
Collection (ATCC), (Rockville, MD). Primary human bronchial epithelial cells (HBEC) were 
obtained by bronchial brushing from healthy volunteers, and cultured as previously described 
(12, 14, 15). 
Virus stocks- Rhinovirus type 16 (RV16 - a major group rhinovirus) was obtained from the MRC 
Common Cold Unit, Salisbury, UK. Viral stocks were prepared by infection of sensitive cell 
monolayers (Ohio HeLa, O’HeLa) as described elsewhere (12, 15). TCID50/ml values were 
determined and rhinovirus serotype was confirmed by neutralization with serotype specific 
antibodies (ATCC) (16). Filtered virus stocks were used as negative control. Virus at multiplicity 
of infection (MOI) of 1 was used for all the experiments. 
Infections, harvesting of cells,  preparation of cell homogenates and preparation of membrane 
and cytosolic fractions- Confluent A549 or HBEC cells were exposed to rhinovirus, medium 
alone, or filtered virus (f-RV) inoculum for different time intervals (20 min - 8 hr). Cell layers 
were thereafter washed three times in cold phosphate-buffered saline (PBS) before harvesting by 
scraping. Harvested cells were centrifuged and the cell pellet was resuspended in phosphate 
buffer (10 mM, pH 7,2). Cell lysis was obtained by repeated (three times) freezing and thawing. 
For preparation of cytosolic fractions, the cell homogenate was then ultracentrifuged at 20,000 g 
for 30 mins, the cell fragments were pelleted and the supernatant (cytosol) collected. Where 
indicated, to obtain membrane fraction, the cell homogenates were centrifuged at 800 g for 10 
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min to separate nuclei from cell membranes. Supernatants were harvested and were again 
centrifuged at 2,000 g, supernatants discarded and membrane pellets diluted in 0.1 M sucrose 
solution. A final centrifugation at 11,000 g for 20 min was performed at 4 °C. Pellets containing 
membranes were diluted in 100 µl of PBS buffer. Protein content was determined 
photometrically using the Bio-Rad protein assay (Bio-Rad). 
Protease and XO inhibition- In selected experiments cells were pretreated, before infection, as 
follows: 12 hr [0.25 to 10 mM] GSH (Sigma), or 12 hr [0.25 to 2.5 mM] SH2 (Acqua Breta, Riolo 
Terme, Ravenna, Italy) or 4 hr [20 µM] oxypurinol (4, 6-dihydroxyprazol (3,4-d) pyrimidine - 
Sigma), a permanent inactivator of xanthine oxidase (17). Where indicated, a 4 hr pretreatment 
with antiproteases ([0.625 µM] serine protease inhibitor phenylmethyl sulphonyl fluoride 
(PMSF), or [1.25 µM] serine and cysteine protease inhibitor leupeptin (Leu), or [1.25 µM] 
aspartic protease inhibitor pepstatin (Pep), or [1.25 µM] serine protease inhibitor aprotinin (Apr), 
or [1.25 µM] metalloprotease inhibitor phenanthroline (Phe) or cysteine protease inhibitor E-64 - 
all from Sigma) or diluent alone was performed (18-23). Diluent was made of phosphate buffer 
pH 7.2 maximal final concentration 0.4%. PMSF only was previously resuspended in ethanol 
before dilution in PBS. Antiproteases were removed immediately before infection. 
Cytochrome c reduction kinetics- The intracellular production of O2- was spectrophotometrically  
evaluated by superoxide dismutase (SOD)-inhibitable cytochrome c reduction kinetics, as 
previously described (12, 24). Kinetics were carried out in 2 ml quartz cuvettes at 37°C for 20 
min in a Uvikon 860 (Kontron Instruments) spectrophotometer in the presence or in the absence 
of superoxide dismutase (SOD, 500 IU/ml, Sigma). Concentration of cytochrome c from beef 
heart (Sigma) was 10-5 M. Absorbance readings were taken at 550 nm (peak of reduced 
cytochrome). Newly generated O2- was measured in each sample and expressed as µM, according 
to standardized procedures (13). Measurements were based on absorbance differences in the 
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presence or absence of SOD, after 5 min of kinetics, when the kinetic slope of cytochrome c 
reduction was steepest. Data were normalized per mg of protein. 
Uric acid kinetics- Uric acid kinetics were performed at 1 hr infection to evaluate the 
involvement of XD/XO in rhinovirus induced O2- generation, as uric acid represents the other 
end-product of xanthine degradation by XO. Uric acid kinetics were spectrophotometrically 
monitored at 293 nm in a UviKon spectrophotometer (Kontron), according to standard 
procedures (25, 26), on 500 µl supernatant collected in PBS, pH 7.4, after addition of xanthine 
(0.1 mM, Sigma). After 15 min of kinetics, uricase (1.0 units/ml) was added to evaluate the 
amount of uric acid produced. 
NADPH oxidase assay- NADPH oxidase assay was performed at different time intervals (20 min 
- 3 hr) to evaluate the involvement of this system in rhinovirus induced O2- generation. Cell 
homogenates were centrifuged as described above to separate nuclei from cell membranes. To 
reconstitute NADPH oxidase, supernatants containing membranes were centrifuged again at 
40,000 g. The reaction mixture contained 200 µl supernatant and 50 µl of diluted membrane 
pellet. After 2 min, 200 µM NADPH and 5 mM MgCl2 were added in the presence or in the 
absence of the specific inhibitor of NADPH oxidase diphenylene iodonium chloride (DPI [0.92 
µg/ml], Sigma) (27). Cytochrome c was added to a concentration of 0.1 mM and PBS (pH 7.2) to 
a final volume of 0.5 ml, and the reduction kinetics was monitored for 15 min at 37 °C as 
previously described. 
Western blot analysis for xanthine dehydrogenase/oxidase. Whole cell proteins were extracted 
from A549 cells as previously described (28). At least 50 μg/lane of whole-cell proteins were 
subjected to a 4-12% tris-glycine gel electrophoresis, and transferred to nitrocellulose filters by 
blotting. Filters were blocked for 45 minutes at room temperature in Tris-buffered saline (TBS), 
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0.05% Tween 20, 5% non-fat dry milk. The filters were then incubated with rabbit anti human 
XD/XO (LS-C26419; from LifeSpan Biosciences) for 1h at room temperature in TBS, 0.05% 
Tween 20, 5% non-fat dry milk at dilution of 1:500.  Filters were washed three times in TBS, 
0.5% Tween 20 and after incubated for 45 minutes at room temperature with goat anti-rabbit 
antibody conjugated to horseradish peroxidase (Dako) in TBS, 0.05% Tween 20, 5% non-fat dry 
milk, at dilution of 1:4000. After further three washes in TBS, 0.05% Tween 20 visualization of 
the immunocomplexes was performed using the ECL as recommended by the manufacturer 
(Amersham Pharmacia Biotech). As an internal control we reprobed each filter with an anti-
human actin antibody (Santa Cruz Biotechnology).  The 145kDa and 85 kDa bands of the 
XD/XO system [(full length XD and the post cleavage fragment containing the active site 
respectively (29, 30)]  and the 43kDa (actin) band were quantified using densitometry with 
VisionWorks®LS software (UVP) and expressed as the ratio with the corresponding actin optical 
density value of the same lane.  
Knockdown of xanthine dehydrogenase expression. RNA interference was used to specifically 
suppress expression of XD in A549 cells. Cells were transfected in 6 well plates with small 
interfering RNA (siRNA) using siPORTTM NeoFXTM Transfection Agent (Applied Biosystem), 
as described by the manufacturer. The following siRNA (all from Ambion) were used: siRNAs 
for XD (s14918; target sequence: sense:  GCAUCGUCAUGAGUAUGUAtt, antisense: 
UUUAUAGCAUCCUCAAUUGtg),  siRNA for GAPDH  (4390849) and nonsilencing siRNA 
(4390843). Total mRNA was extracted by using RiboPureTM kit (Ambion) as per 
manufacturer’s instructions. 1 µg of mRNA was used to perform reverse transcription assay with 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystem). XD mRNA expression 
was monitored by Real Time RT-PCR by using TaqMan® Gene Expression Assay (Applied 
Biosystem) specific for XD (Cat. n. Hs00166010_m1) following the manufacturer’s 
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recommendations.  The reaction was carried out in a Rotor-GeneTM 6000 instrument (Corbett 
Life Science). Results were normalized to 18S rRNA (sense: 5’- CGC CGC TAG AGG TGA 
AAT TCT -3’, antisense:  5’-  CAT TCT TGG CAA ATG CTT TCG-3’ 300nM each, probe: 5’-
FAM ACC GGC GCA AGA CGG ACC AGA TAMRA-3’ 175nM) and expressed as XD mRNA 
relative levels as compared to nonsilencing siRNA transfected cells  by using the RotorGene 
software (Corbett Research) and the two standard curve method for relative quantitation (31). 
High performance liquid chromatography (HPLC) analysis of intracellular GSH- A549 cells 
were cultured at 85% confluence, incubated with RV16, medium alone or f-RV for different 
periods (20 min to 1 hr) then trypsinized, collected and harvested in cryovials with 1.2 ml 3% 
metaphosphoric acid in sterile conditions to avoid GSH oxidation and finally frozen in liquid 
nitrogen until used. Cell homogenate was obtained and protein content was determined as 
previously described. Intracellular GSH concentration was evaluated by HPLC in a Kontron 
Instruments apparatus (Milan, Italy) equipped with a C18 hydrophobic column (5 um particle 
size, 4.6 x 250 mm), a 420 pump (range 0.005-10 ml/min), a 425 gradient former and injection 
valve with 20-µl sampling loop. Elution was carried out at room temperature in isocratic gradient 
(75% methanol and KH2PO4 buffer, pH 3, 1 ml/min speed). GSH was analyzed at 200 nm by a 
432 UV detector (Kontron) with IBM integrated software PC Pack. Homogenates of cells were 
centrifuged at 40,000 g for 20 min at 4 °C and the supernatant collected and concentrated on 
Amicon Ultra 10,000 centrifugal filter devices (Millipore, Bedford, MA) to a final volume of 
about 300 µl. Samples were analysed without derivatisation against standards of pure lyophilised 
GSH (Biomedica Foscama), diluted in 1 ml normal saline solution. The final concentration was 
obtained by serial dilutions of the lyophilized product. In selected experiments cells were 
pretreated, before infection, as previously described, for 12 hr with GSH, SH2 (0.25 to 2.5 mM) 
or 4 hr oxypurinol (20 µM). Where indicated, a 4 hr pretreatment with protease inhibitors (PMSF 
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[0.625 µM]; Leu [1.25 µM]; Pep [1.25 µM]; Apr [1.25 µM]; Phe [1.25 µM]; E-64 [1.25 µM]) or 
diluent was performed. All protease inhibitors were removed immediately before infection. 
ELISA assays for chemokines- Subconfluent A549 cells were pretreated for 4 hr with oxypurinol 
(20 µM) before RV16 or f-RV inoculum or medium alone treatment. After 1 hr infection 
unbounded virus was removed and fresh medium added. Supernatants were harvested at 4 hr and 
levels of IL-8, and GRO-α were assessed using commercially available ELISA kits (R&D 
System) following manufacturer’s instruction. Detection limits for IL-8 and GRO-α ELISA assay 
were approximately 10 pg/ml and 15 pg/ml respectively.  
NF-kB transcription factor activation. Nuclear extracts were prepared from A549 cells using the 
Nuclear Extract Kit (Active Motif). NF-kB activation was assessed in A549 cell nuclear extracts 
using the TansAM p65 Transcription Factor Assay Kit (Active Motif) following manufacture’s 
recommendations. Nuclear extract of Jurkat cells provided by the manufacture (Active Motif) 
were used as positive controls. 
Statistical Analysis- Group data were expressed as mean and standard error (SEM). Analysis of 
variance was used to determine differences between groups. Paired or unpaired Student’s t tests 
were performed after the analysis of variance when appropriate. All experiments were carried out 
at least 5 times. Bonferroni adjustment was applied where indicated. A probability value of 
<0.05, was considered significant. 
 
Results 
 
Rhinovirus induced O2- production in respiratory epithelial cells is cytosolic not membrane 
associated. O2- production was evaluated by superoxide dismutase (SOD)-inhibitable cytochrome 
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c reduction kinetics. Since other workers had implicated NADPH oxidase in RV induction of 
reactive oxygen species (32) and since NADPH oxidase is a membrane bound system, we first 
sought to identify the cellular  site of O2-  production. In the search of cellular sources of RV16 
induced O2- production, we first confirmed our previous findings of rapid induction of O2- by 
RV16 in membrane free cytosolic fractions (Figure 1). To investigate membrane production, 
directly O2- production was evaluated in cell membranes obtained from A549 epithelial cells 
infected with RV16. No induction was observed (P=0.82 vs unstimulated controls) at any time 
point (20, 60, 120, 180, 240, 300, 360, 420, 480 min), indicating that the cytosol, not the 
membrane, is the site of RV16 induced O2- production.  
 
Rhinovirus induction of O2- is independent of the NADPH oxidase system. We investigated 
whether rhinovirus induced O2- production could derive from the activity of NADPH oxidase, in 
experimental conditions where both the cytosolic and membrane fractions of the homogenates 
were pooled together. The membrane fractions were added, together with the substrate of 
NADPH oxidase, NADPH, in the presence and absence of an inhibitor of the NADPH enzyme 
system, diphenylene iodonium chloride (DPI) (27). NADPH addition would increase O2- 
production if production is NADPH oxidase-dependent. We found that both the addition of 
NADPH and of DPI (Figure 2A) to the reaction mixture did not change O2- production induced 
by RV16 infection, indicating that the NADPH oxidase system is not relevant to early O2- 
generation induced by RV16.  
 
 
Rhinovirus induces O2- production via the XD/XO enzyme system. To confirm that O2- is 
generated via the XD/XO enzyme system, we next investigated RV induction of uric acid, the 
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other product, besides O2-, of XO degradation of the purine base xanthine. These experiments 
were conducted at 1 hr after infection, i.e. at the peak of O2- generation. Uric acid was detected 
only in RV16 infected samples. Its identification was confirmed by addition, after 15 min of the 
kinetic assay, of uricase, which degrades uric acid to allantoin (25, 26). As expected, uric acid 
was rapidly degraded by uricase confirming the XD/XO system was activated by rhinovirus 
infection. Similar findings were observed in homogenate samples obtained from HBEC, in the 
same experimental conditions , confirming rhinovirus activation of XD/XO in primary cells. To 
further confirm the role of XD/XO enzyme system in O2- production we performed experiments 
in presence of oxypurinol, a permanent inactivator of the oxidase form of the enzyme (XO), the 
only form of the enzyme able to produce O2- (17). At 1 hr infection RV16 induced cytosol O2- 
production was completely quenched when A549 cells were pretreated with oxypurinol (Figure 
2B). Similar findings were observed in homogenate samples obtained from HBEC in the same 
experimental conditions as in both cases oxypurinol reduced O2- production to levels observed 
with medium or diluent alone or inactivated virus. 
 
Rhinovirus induces proteolytic activation of XD/XO enzymatic system. In other experimental 
systems, the XD/XO enzymatic system is able to produce O2- when is converted to the oxidase 
form by proteolytic activity, exerted by a serine protease, which partially hydrolyzes the enzyme 
to its active form (29, 33). To investigate the mechanisms of rhinovirus induction of XD/XO, 
cells were next infected in the presence or absence of serine protease inhibitors, or with cysteine 
or metalloprotease inhibitors as controls. RV16 infection (20 min to 1 hr) failed to generate O2- in 
the cytosol when epithelial cells were pretreated for 4 hr with protease inhibitors phenylmethyl 
sulphonyl fluoride (PMSF), or leupeptin (Leu), pepstatin (Pep), aprotinin (Apr), which all act as 
serine protease inhibitors (Figure 3A). Serine protease involvement was confirmed as neither the 
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metalloprotease inhibitor phenanthroline (Phe – Figure 3B) nor the cysteine protease inhibitor E-
64 (Figure 3B) (18-23) had any effect on rhinovirus induction of O2-. This data confirm the 
involvement of specific proteolytic mechanisms mediated by serine proteases in rhinovirus 
induced activation of XO. To directly evaluate the effects of RV infection on XD/XO proteins, 
we performed western blotting analysis using an antibody able to recognize XD/XO expression. 
The 145 kDa band corresponding to full length XD was significantly reduced at 30 min (2 fold; 
p<0.05) and at 1 hr (4 fold; p<0.01) after RV16 infection as compared to uninfected control cells 
(p<0.05). Such a reduction was paralleled by 2 fold-increased expression of the 85 kDa band, 
containing the active site, at 1 hr infection  (p<0.05). By measuring XD/XO ratio we found a 
progressive significant reduction at 30 min and 1 hr after RV16 infection as compared to 
uninfected control cells (3 fold; p<0.05 and 10 fold; p<0.01, respectively). Moreover 4hr serine-
protease inhibitor Apr, but not 4 hr cysteine-inhibitor E64 pretreatment, abolished XD cleavage.  
 
XD knockdown reduces rhinovirus induced O2- production. To further confirm the role of the 
XD/XO system in rhinovirus-induced O2- production, we performed experiments in which XD 
expression in A549 cells was knocked down by siRNA. Transfection of XD siRNAs resulted in 
marked suppression of XD mRNA expression as compared to scrambled siRNA transfected cells, 
with a peak of inhibition at 24hr. At this time point, XD knockdown suppressed RV16-induced 
O2- production spectrophotometrically  measured by SOD-inhibitable cytochrome c reduction 
kinetics (Figure  4). Control siRNAs had no effect either on XD mRNA expression (Fig 4D) or 
on RV16-induced O2- production (Figure 4).  
 
Rhinovirus depletes intracellular reduced gluthathione (GSH). To investigate the consequences 
of RV-induced O2- production on intracellular redox equilibrium, we evaluated whether the 
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concentration of the intracellular reducing agent GSH is modified by RV16 infection. In A549 
cells, as the duration of RV16 infection increased, endogenous stores of GSH were progressively 
reduced and complete depletion was observed at 1 hr after infection (Figure 5 left panel). As 
observed with O2- induction, RV16 induced depletion of intracellular GSH at 1 hr after infection 
was completely inhibited when A549 cells were pretreated with either oxypurinol or serine 
protease inhibitors, but not with metalloprotease inhibitor phenanthroline (Phe) or cysteine 
protease inhibitor (E-64). 
 
Increasing intracellular GSH inhibits rhinovirus induced intracellular GSH depletion and O2- 
production. Since reduction of intracellular reducing power is “per se” a known mechanism of 
activation of XO (34, 35), we next investigated whether by increasing intracellular GSH with the 
reducing agents SH2 or exogenous GSH, we could block the activation of XO induced by RV 
infection. We first showed that pretreatment of A549 cells with SH2 and exogenous GSH 
increased intracellular GSH levels in a dose-dependent manner. A549 cells were then pretreated 
for 12 hr with 2 mM SH2 to enhance intracellular GSH and then infected for 1 hr with RV16. No 
reduction of endogenous GSH was observed after 1 hr RV16 infection, confirming that 
enhancing intracellular GSH protected cells against virus induced GSH depletion. Similar 
protection was observed with 10 mM exogenous GSH (data not shown) treatment before the 
infection. Pretreatment with either 2 mM SH2 or 10 mM exogenous GSH, not only increased 
intracellular GSH levels but also completely inhibited RV16 induced O2- production at 1 hr after 
infection, as assessed by SOD-inhibitable cytochrome c reduction assay (Figure 5 right panel). In 
these experiments uric acid production was similarly suppressed.  
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XO inhibition reduces rhinovirus induced chemokine production. RV 
infection of bronchial epithelial cells induces the expression of several proinflammatory 
cytokines, including many that are involved in neutrophil chemoattraction and activation [i.e 
interleukin(IL)-8 and Gro-α]. Neutrophil inducing cytokines are not effectively suppressed by the 
currently available asthma therapies, i.e. steroids or long acting beta agonists (2). Since the 
induction of these mediators occurs through oxidative sensitive pathways [e.g. NF-kB signaling 
activation (6)], we evaluated whether oxypurinol inhibition of XO mediated O2- generation 
affects rhinovirus induced IL-8 and Gro-α production in A549 respiratory epithelial cells. 
Significant induction of IL-8 and Gro-α was apparent at 4 hr post RV16 infection. Oxypurinol 
pre-treatment significantly reduced both IL-8 and Gro-α RV16-induced production, while diluent 
had no effect.  
 
Effect of rhinovirus infection on NF-kB activation. Modulation by oxypurinol. To assess whether 
rhinovirus infection activates NF-kB and whether this is mediated by O2-production, we 
measured activated NF-kB in nuclear extracts in A549 cells following RV16 infection with or 
without 4hr oxypurinol  pretreatment. p65 nuclear concentration was 40.7 ± 6.3 pg/µl in 
unstimulated conditions.  In accordance with previous data (12, 15) we found that 30 min RV16 
infection significantly induced p65 nuclear translocation (2-fold vs unstimulated; p<0.05). Four 
hr pre-treatment with 20µM oxypurinol significantly inhibited RV16 induced NF-kB activation 
(p<0.05 vs RV16 infected cells not pretreated).   
 
Conclusion 
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In this study we found that O2- generation induced by rhinovirus infection is initiated by 
proteolytic activation of the XD/XO enzyme system. Consequently, newly generated O2- leads to 
progressive depletion of intracellular GSH storage, a condition that can further activate the 
XD/XO system. Inhibition of XO activity completely abolished rhinovirus induced O2- 
production and intracellular GSH depletion, as did a variety of serine protease inhibitors. We also 
found that by enhancing intracellular GSH storage with exogenous SH2 or GSH rhinovirus 
infection was rendered unable to induce O2- production and to affect intracellular GSH levels. 
Several studies have described oxidant generation following respiratory virus infection both in 
vitro and in vivo (9, 36). In some studies a role for virus induced oxidants in the production of 
inflammatory responses/mediators has been identified (37). However the molecular mechanisms 
regulating generation of oxidant species by viruses in biological systems have never been fully 
investigated. 
The findings of the present study indicate a complex mechanism of oxidant induction following 
activation of XO induced by rhinovirus infection (Figure 6). A “vicious circle” would represent 
the final scenario where activation of XO, initiated immediately after infection via proteolysis of 
XD to XO, is thereafter implemented via a non-proteolytic mechanism mediated by oxidative 
consumption of intracellular reducing capacity via depletion of GSH stores. Depletion of 
intracellular reducing agents is a known mechanism of activation of XO and O2- production (34, 
35). The involvement of rhinovirus induced oxidants in GSH consumption was confirmed by the 
finding that, when XO activation was inhibited, rhinovirus infection did not result in GSH 
depletion. The sequence of events represented in Fig. 9 is supported by the timing of the different 
steps involved, with O2- production being rapidly induced 20 min after infection (Fig. 1), while 
GSH depletion is undetectable 20 min after infection and thereafter progressively increases for 40 
min, being complete at 60 min after infection (Fig. 5 A & B). The fact that in a reducing 
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environment no uric acid was produced and that the intracellular concentration of GSH was 
unchanged after rhinovirus infection confirms the inverse relationship between GSH intracellular 
concentration and XO activation. The involvement of a NADPH oxidase-like enzyme in 
rhinovirus induced oxidative stress has been previously described (32). In contrast to the study by 
Kaul and colleagues, our study focuses strictly on the early oxidative events occurring within 
cells immediately after rhinovirus infection (with a peak at 1 hr after infection). Also, by using a 
method able to specifically detect newly generated  O2-, i.e. the SOD-inhibitable cytochrome c 
reduction assay (38), we directly evaluated O2- intracellular production, and not oxidative stress 
in general. Moreover, at variance with Kaul and colleagues, we employed oxypurinol, which 
completely inactivates XO by direct binding to the enzyme active site (17), and not allopurinol, 
which only partially inhibits the enzyme. Treatment with oxypurinol completely abolished 
rhinovirus induced O2- generation, thus confirming the specificity of our findings on XO 
activation. These and other difference between the two studies, in particular different samples for 
analyses (intracellular vs extracellular compartments) and different timing are likely explanations 
for the different results reported.  
Despite the effort and resources expended, no antiviral drugs are currently marketed for the 
prevention or treatment of rhinovirus infection (39). In the absence of effective anti-viral 
therapies, development of therapies that blocked the inflammatory responses to infection would 
be a major advance. Our demonstration of the molecular mechanisms by which rhinovirus 
activates oxidant generation, a crucial step in the complex inflammatory response to infection, 
(12, 32) could open new possibilities in the search for therapeutic targets for future intervention. 
In particular, the documentation that: a) exogenous interventions able to increase intracellular 
reducing agent storage can block rhinovirus-mediated activation of the vicious circle that leads to 
sustained production of  O2-, and b) inhibition of XO, with protease inhibitors or specific 
inhibito
promisi
common
Figure 
Figure. 
bronchi
 
rs (oxypur
ng options 
 cold and e
1 
1. Rhinov
al epithelial
inol) inhib
for the deve
xacerbatio
iruses-indu
 cells (HBE
 
its O2- a
lopment of
ns of asthm
ced produ
C). 
129 
 
nd pro-inf
 treatment 
a and COP
ction of s
lammatory
for rhinovir
D. 
uperoxide 
 mediator 
us induced
anion (O2
productio
 diseases in
-) in hum
n, indicate
cluding the
an primary
  
 
 
 
Figure 2
Figure 2
Xanthin
product
(DPI) w
medium
with (d
HBEC w
RV16), 
pretreat
(Oxy) o
 
: superoxi
e oxidase 
ion. (A) O2
as added to
 alone (dia
ashed line)
ere expos
medium a
ment befor
r RV16 (Ox
de anion (O
(XO) invo
- productio
 the reacti
monds) or
 NADPH] 
ed for 1 hr
lone (Medi
e the infec
y+RV16). 
2
-) product
lvement in
n was not 
on mixture
 life RV16
confirming
 to life RV
um) or dil
tion with o
130 
 
A
ion is inde
 rhinovirus
changed w
 [RV16 phy
 infection 
 lack of in
16 (RV16)
uent alone 
xypurinol a
 
pendent of
 induced 
hen a spec
sically rem
(black circl
volvement
, RV16 ph
(Diluent). 
nd than ex
B 
 the NADP
cytosolic s
ific inhibito
oved by fi
es), withou
 of NADP
ysically rem
Where ind
posed for 
H oxidase 
uperoxide 
r of NAD
ltration (op
t (continuo
H oxidase 
oved by f
icated cells
1 hr to me
system and
anion (O2-)
PH oxidase
en circles)
us line) or
(N=5). (B)
iltration (f
 were 4 hr
dium alone
  
 
 
 
, 
 
 
-
 
 
Figure 
Figure 
product
leupepti
A549 c
protease
indicate
RV16 o
p<0.001
3 
3: Effects 
ion. Effect
n (Leu), pe
ells (N=5).
 inhibitor 
d (+) cells 
r medium 
 vs medium
of protease
s of serine
pstatin (Pe
 Effects of
E-64 (C) o
were 4 hr p
alone. (In 
 alone trea
 inhibitors 
 protease 
p), aprotin
 metallo-p
n RV16 in
retreated w
panel A *
ted cells wi
131 
 
on rhinovir
inhibitors 
in (Apr) on
rotease inh
duced cyto
ith proteas
** p<0.00
th or witho
us induced
phenylmet
 RV16 ind
ibitor Phen
solic O2- p
e inhibitors
1 vs all ot
ut inhibitor
 cytosolic 
hyl sulpho
uced cytos
anthroline
roduction 
, then expo
her conditi
s pre-treatm
superoxide 
nyl fluorid
olic O2- pr
(Phe) (B) 
in A549 c
sed, for 20 
ons, in pa
ent). 
  A 
  B 
anion (O2-)
e (PMSF)
oduction in
or cysteine
ells. Where
min or 1 hr
nels B ***
  
 
, 
 
 
 
 
 
Figure 
Figure 
Superox
medium
infected
 
4 
4: Effect 
ide anion 
 alone, non
 cells in all
of XD kn
production
silencing s
 other expe
 
ock-down 
 following 
iRNA, GA
rimental co
132 
 
on rhinovi
1 hr RV1
PDH siRNA
nditions.).
rus induce
6 infection
 and XD 
d superox
 in A549 
siRNA. (N
ide anion 
cells trans
= 3, *p<0.0
production
fected with
5 vs RV16
  
 
. 
 
 
Figure 
 
Figure 
(GSH) c
chromat
(dashed
exogeno
5 
5: (Left pa
oncentratio
ography (H
 line) for 20
us SH2 and
nel) Effect 
n in A549 
PLC) in A
 min to1 h
 GSH pre-t
of rhinovir
cells. Intra
549 cells in
r. (N=5, **
reatment on
133 
 
us (RV) in
cellular GS
cubated wi
* p<0.001 
 RV16 sup
fection on
H was eval
th RV16 (c
vs control 
eroxide an
 intracellul
uated by h
ontinuous 
samples). (R
ion product
ar reduced 
igh perform
line), or me
ight panel
ion.  
glutathione
ance liquid
dium alone
) Effects o
  
 
 
 
 
f 
Figure 6
Figure 
product
xanthine
xanthine
capacity
activatio
increase
mechan
anion; X
glutathi
 
 
 
6: Propos
ion. Follow
-dehydrog
 (2). Intra
 (including
n via a no
d intracellu
isms of xa
O = xanth
one). 
ed mecha
ing rhinov
enase (1). O
cellular ox
 reduced g
n-proteoly
lar reducin
nthine oxid
ine-oxidase
 
nisms of 
irus infec
2
- and uric
idant produ
lutathione 
tic mechan
g capacity
ase activat
; XD = xan
134 
 
rhinovirus 
tion xanthi
 acid are th
ction resul
depletion) (
ism (4). A
 (green pa
ion initiate
thine-dehy
induced c
ne-oxidase
ereafter pro
ts in the d
3), which 
ntiprotease
thways) re
d by rhinov
drogenase;
ytosolic su
 is activat
duced from
epletion of
in turns ind
shield and
spectively 
irus infect
 XA = xant
 
peroxide a
ed via pro
 the enzym
 intracellul
uces xanth
 exogenou
block the t
ion (O2- = 
hine; GSH
nion (O2-)
teolysis of
e substrate
ar reducing
ine-oxidase
sly induced
wo distinc
superoxide
 = Reduced
  
 
 
 
 
 
 
t 
 
 
  
135 
 
References 
 
1. Papadopoulos NG, Bates PJ, Bardin PG, Papi A, Leir SH, Fraenkel DJ, Meyer J, Lackie PM, 
Sanderson G, S.T. H, et al. Rhinoviruses infect the lower airways. J Infect Dis 2000;181:1875-
1884. 
2. Edwards MR, Haas J, Panettieri RA, Jr., Johnson M, Johnston SL. Corticosteroids and beta2 
agonists differentially regulate rhinovirus-induced interleukin-6 via distinct cis-acting elements. J 
Biol Chem 2007;282:15366-15375. 
3. Edwards MR, Hewson CA, Laza-Stanca V, Lau H-TH, Mukaida N, Hershenson MB, Johnston 
SL. Protein kinase r, ikappab kinase-beta and nf-kappab are required for human rhinovirus 
induced pro-inflammatory cytokine production in bronchial epithelial cells. Molecular 
Immunology 2007;44:1587-1597. 
4. Fraenkel DJ, Bardin PG, Sanderson G, Lampe F, Johnston SL, Holgate ST. Lower airways 
inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care 
Med 1995;151:879-886. 
5. Calhoun WJ, Dick EC, Schwartz LB, Busse WW. A common cold virus, rhinovirus 16, 
potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. 
J Clin Invest 1994;94:2200-2208. 
6. Caramori G, Papi A. Oxidants and asthma. Thorax 2004;59:170-173. 
7. Li N, Karin M. Is nf-kappab the sensor of oxidative stress? Faseb J 1999;13:1137-1143. 
8. Janssen-Heininger YM, Poynter ME, Baeuerle PA. Recent advances towards understanding 
redox mechanisms in the activation of nuclear factor kappab. Free Radic Biol Med 
2000;28:1317-1327. 
  
136 
 
9. Peterhans E. Oxidants and antioxidants in viral diseases: Disease mechanisms and metabolic 
regulation. J Nutr 1997;127:962S-965S. 
10. Casola A, Burger N, Liu T, Jamaluddin M, Brasier AR, Garofalo RP. Oxidant tone regulates 
rantes gene expression in airway epithelial cells infected with respiratory syncytial virus. Role in 
viral-induced interferon regulatory factor activation. J Biol Chem 2001;276:19715-19722. 
11. Zsengeller ZK, Ross GF, Trapnell BC, Szabo C, Whitsett JA. Adenovirus infection increases 
inos and peroxynitrite production in the lung. Am J Physiol Lung Cell Mol Physiol 
2001;280:L503-511. 
12. Papi A, Papadopoulos NG, Stanciu LA, Bellettato CM, Pinamonti S, Degitz K, Holgate ST, 
Johnston SL. Reducing agents inhibit rhinovirus-induced up-regulation of the rhinovirus receptor 
intercellular adhesion molecule-1 (icam-1) in respiratory epithelial cells. Faseb J 2002;16:1934-
1936. 
13. Halliwell B, Gutteridge J. Free radical bilogy & medicine. Oxford, UK: Oxford, University 
Pess; 1999. 
14. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, Holgate ST, 
Davies DE. Asthmatic bronchial epithelial cells have a deficient innate immune response to 
infection with rhinovirus. J Exp Med 2005;201:937-947. 
15. Papi A, Johnston SL. Rhinovirus infection induces expression of its own receptor intercellular 
adhesion molecule 1 (icam-1) via increased nf-kappab- mediated transcription. J Biol Chem 
1999;274:9707-9720. 
16. Johnston SL, Tyrrell DAJ. Rhinoviruses. In: Lennette EH, Schmidt NJ, editors. Diagnostic 
procedures of viral, rickettsial and clamydial infections. Washington (DC): American Public 
Health Association; 1997. p. 553-563. 
  
137 
 
17. Spector T. Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide 
radical. Biochem Pharmacol 1988;37:349-352. 
18. Stracher A. Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. Ann N 
Y Acad Sci 1999;884:52-59. 
19. Bhattacharya S, Ghosh S, Chakraborty S, Bera AK, Mukhopadhayay BP, Dey I, Banerjee A. 
Insight to structural subsite recognition in plant thiol protease-inhibitor complexes : 
Understanding the basis of differential inhibition and the role of water. BMC Struct Biol 
2001;1:4. 
20. Kageyama T. Pepsinogens, progastricsins, and prochymosins: Structure, function, evolution, 
and development. Cell Mol Life Sci 2002;59:288-306. 
21. Wegner J. Biochemistry of serine protease inhibitors and their mechanisms of action: A 
review. J Extra Corpor Technol 2003;35:326-338. 
22. Yeh CT, Lai HY, Chu SP, Tseng IC. Anti-sense expression of a metallopeptidase gene 
enhances nuclear entry of hbv-DNA. Biochem Biophys Res Commun 2004;323:32-37. 
23. Tamai M, Matsumoto K, Omura S, Koyama I, Ozawa Y, Hanada K. In vitro and in vivo 
inhibition of cysteine proteinases by est, a new analog of e-64. J Pharmacobiodyn 1986;9:672-
677. 
24. Pinamonti S, Muzzoli M, Chicca MC, Papi A, Ravenna F, Fabbri LM, Ciaccia A. Xanthine 
oxidase activity in bronchoalveolar lavage fluid from patients with chronic obstructive pulmonary 
disease. Free Radic Biol Med 1996;21:147-155. 
25. Priest DG, Pitts OM. Reaction intermediate effects on the spectrophotometric uricase assay. 
Anal Biochem 1972;50:195-205. 
26. Bartl K, Brandhuber M, Ziegenhorn J. Improved automated kinetic determination of uric acid 
in serum by use of uricase/catalase/aldehyde dehydrogenase. Clin Chem 1979;25:619-621. 
  
138 
 
27. Morre DJ. Preferential inhibition of the plasma membrane nadh oxidase (nox) activity by 
diphenyleneiodonium chloride with nadph as donor. Antioxid Redox Signal 2002;4:207-212. 
28. Varani K, Caramori G, Vincenzi F, Adcock I, Casolari P, Leung E, Maclennan S, Gessi S, 
Morello S, Barnes PJ, et al. Alteration of adenosine receptors in patients with chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med 2006;173:398-406. 
29. Hille R, Nishino T. Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine 
dehydrogenase. Faseb J 1995;9:995-1003. 
30. Harrison R. Structure and function of xanthine oxidoreductase: Where are we now? Free 
Radic Biol Med 2002;33:774-797. 
31. Bustin SA. Absolute quantification of mrna using real-time reverse transcription polymerase 
chain reaction assays. Journal of molecular endocrinology 2000;25:169-193. 
32. Kaul P, Biagioli MC, Singh I, Turner RB. Rhinovirus-induced oxidative stress and 
interleukin-8 elaboration involves p47-phox but is independent of attachment to intercellular 
adhesion molecule-1 and viral replication. J Infect Dis 2000;181:1885-1890. 
33. Enroth C, Eger BT, Okamoto K, Nishino T, Pai EF. Crystal structures of bovine milk 
xanthine dehydrogenase and xanthine oxidase: Structure-based mechanism of conversion. Proc 
Natl Acad Sci U S A 2000;97:10723-10728. 
34. Hassoun PM, Yu FS, Zulueta JJ, White AC, Lanzillo JJ. Effect of nitric oxide and cell redox 
status on the regulation of endothelial cell xanthine dehydrogenase. Am J Physiol 
1995;268:L809-817. 
35. Lee MM, Green FH, Schurch S, Cheng S, Bjarnason SG, Leonard S, Wallace W, Possmayer 
F, Vallyathan V. Comparison of inhibitory effects of oxygen radicals and calf serum protein on 
surfactant activity. Mol Cell Biochem 2004;259:15-22. 
  
139 
 
36. Jobsis RQ, Schellekens SL, Fakkel-Kroesbergen A, Raatgeep RH, de Jongste JC. Hydrogen 
peroxide in breath condensate during a common cold. Mediators Inflamm 2001;10:351-354. 
37. Psarras S, Caramori G, Contoli M, Papadopoulos N, Papi A. Oxidants in asthma and in 
chronic obstructive pulmonary disease (copd). Curr Pharm Des 2005;11:2053-2062. 
38. McCord JM, Fridovich I. Production of o2- in photolyzed water demonstrated through the use 
of superoxide dismutase. Photochem Photobiol 1973;17:115-121. 
39. Jefferson TO, Tyrrell D. Withdrawn: Antivirals for the common cold. Cochrane Database 
Syst Rev 2007;18:CD002743. 
 
 
  
  
140 
 
 
Human model of rhinovirus induced asthma exacerbations 
 
 
Simon D Message1,4, Vasile Laza-Stanca1, Patrick Mallia1, Hayley L Parker1, Jie Zhu2, 
Tatiana Kebadze1, Marco Contoli1,3,4, Gwen Sanderson1, Onn M Kon4, Alberto Papi3, Peter K 
Jeffery2, Luminita A Stanciu1, Sebastian L Johnston1,4 
 
 
1Department of Respiratory Medicine, National Heart and Lung Institute, Imperial College, 
London, UK. 
 
2Lung Pathology, National Heart and Lung Institute, Imperial College, London, UK. 
 
3 Research Centre on Asthma and COPD, University of Ferrara, Ferrara, Italy 
 
4 Imperial Healthcare NHS Trust, London, UK 
 
 
  
141 
 
Background, Aims and Summary 
 
Acute exacerbations are the major cause of asthma morbidity, mortality and health care costs. 
Exacerbations are poorly treated and prevented by current therapies. New therapies are urgently 
needed. The great majority of asthma exacerbations are associated with viral infection. 
Rhinovirus is the commonest virus identified (1-3).  
There is no useful animal model of rhinovirus-induced asthma exacerbations. Experimental 
rhinovirus infection in human volunteers has been used to investigate mechanisms of virus-
induced exacerbations, however no previous study has demonstrated differences between 
asthmatic and normal subjects in lower respiratory physiologic or pathologic responses to 
rhinovirus infection. Here we use experimental rhinovirus infection to investigate lower airway 
physiology, virus load and immunopathology in 10 asthmatic and 15 normal volunteers.  
We found that rhinovirus infection induced significantly greater lower respiratory symptoms, 
reductions in lung function, increases in bronchial hyperresponsiveness and lower airway 
inflammation in asthmatic compared to normal subjects. Virus load was strongly related to 
severity of clinical symptoms, changes in lung function, bronchial hyperresponsiveness and 
lower airway inflammation. Moreover, these virologic and clinical outcomes in asthmatic 
subjects were strongly related to deficient IFN-γ responses and augmented Th2 cytokine 
responses 
This model provides evidence supporting a causal relationship between rhinovirus infection and 
asthma exacerbation, reproduces many features of naturally occurring exacerbations and could be 
used to investigate mechanisms of disease and to test new candidate treatments. 
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Methods 
 
Study design 
RV16 experimental infections were induced in RV16 seronegative atopic asthmatic and normal 
non-atopic adult subjects. Clinical and atopic status were defined by questionnaire, skin prick 
testing, serum IgE and lung function testing including PEF, FEV1, forced vital capacity (FVC) 
and histamine challenge. Normal subjects were taking no medication, asthmatics inhaled short 
acting 2 agonists only. Subjects were free of common cold symptoms for 6 wks before starting 
the study. All were non smokers. Baseline, acute infection and convalescent samples of blood, 
nasal lavage, induced sputum and bronchoalveolar lavage (BAL) were taken. Baseline samples 
were taken 14 days prior to infection and diaries kept to record symptoms and home lung 
function throughout the study. All subjects gave informed consent and the study was approved by 
St Mary’s NHS Trust Research Ethics Committee. 
 
Experimental infection with RV16 
Infection was induced using 10000 TCID50 RV16 on day 0 by nasal spray, as described (4). 
Following inoculation, subjects returned home. 
 
Assessment of blood and airway inflammation and T cell cytokine production 
Blood Coulter counts were performed. Absolute and differential induced sputum and BAL cell 
counts were determined on cytospins. Fresh PBMC and BAL cells were stained for CD4 and 
CD8 T cells and NK and B cells and intracellular type 1 (IFN-γ) and type 2 (IL-4, -5, -13) 
cytokines and IL-10 were determined in CD4+ T cells by 3 and 4 colour flow cytometry (BD 
LSR flow cytometer) as described (5). 
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Bronchoalveolar lavage cell cultures 
Cells from the BAL obtained at baseline bronchoscopy were incubated with medium alone, 
RV16, LPS or PHA. After 48 hours supernatants were harvested and stored at -80°C for cytokine 
analysis by Luminex. 
 
Statistical analysis 
Symptom scores and lung function were corrected for differences at baseline and effects of 
bronchoscopy. Except where otherwise stated data are presented as median and interquartile 
range. Differences during infection from baseline and convalescence were analysed using 
Friedman’s test and if significant Wilcoxon tests. Differences between normal and asthmatic 
groups were analysed using Mann Whitney tests and correlations using Spearman’s rank 
correlation. Results of stimulation of BAL cells were analysed within groups by paired and 
between groups by un-paired parametric or non parametric tests as determined by data 
distribution. 
 
Results 
 
Recruitment and baseline characteristics of subjects 
11 atopic asthmatic and 17 non atopic normal volunteers were recruited into the study. One 
asthmatic and 2 normal volunteers did not continue following the baseline phase. There were no 
serious adverse events and no subject required inhaled or oral steroids for their asthma. 
 
Confirmation of RV16 infection 
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Successful experimental RV16 infection was confirmed in all subjects. These were similar in 
both groups and characteristic of an acute infection, with undetectable virus in most volunteers on 
day 1 following inoculation, followed by a rapid increase in virus loads on day 2 following 
inoculation with a peak around days 2-4. Virus was also detected in the lower airway in both 
groups of subjects. Virus loads in both upper and lower respiratory tracts were between 0.5 and 2 
Logs greater in the asthmatic compared with the normal subjects, however these differences were 
not statistically significant. 
 
RV induction of chest symptoms 
Both groups also had significantly increased chest symptoms during infection. Daily chest scores 
peaked later than cold symptoms for both groups at day 6. Relative to the mean score on days –4 
to 0 there were significant increases in daily chest scores for asthmatic subjects on days 1 and 3-7 
but for normal subjects only on day 6. Daily chest scores were significantly greater in the 
asthmatic group than the normal group on day 3 (p=0.018), day 4 (p=0.002) and day 7 (p=0.021). 
Peak chest score was higher in the asthmatic group [asthmatic 3 (1.5,7.5) v normal 1 (0,3) 
p=0.05] (Figure 1) as were total chest symptoms in the asthmatic subjects [13 (5,25)] compared 
with normal subjects [2(-1,7)], p=0.017. 
 
RV induced reductions in lung function 
RV infection induced no significant changes in PEF or FEV1 in the normal group on any study 
day (p=NS on all days), in the asthmatic group there were significant falls in FEV1 on day 3 and 
5-14 (not shown) and in PEF on days 1-8 and 12-14 (figure 2). In addition the median maximum 
% fall was significantly greater in the asthmatic group for both FEV1 [12.5 (5.1,17.9) v 3.8 
(0.3,6.8), p=0.027] and PEF [10.8 (9.2,30.6) v 4.5 (0.8,9.6) p=0.003]. 
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RV induction of bronchial hyperreactivity 
For the asthmatic group there was a significant reduction in both the PC20 [-0.6 doubling 
dilutions (-0.6,-1.3) p=0.038] and the PC10 histamine [-0.9 (0.1,-1.5) p=0.05] at day 6 relative to 
baseline (Figure 3A). In contrast, there was no significant change in PC10 [0.2 (-0.9, 0.7) p=0.9] 
for the normal group (Figure 3B). As a consequence, at infection, the asthmatics had significantly 
greater bronchial hyperreactivity [day 6 PC10 for asthmatic subjects 0.3 mg/mL vs 6.4 mg/mL 
for normal subjects p<0.001]. 
 
Relationship between clinical illness severity and virus load 
There was a strong significant correlation between total lower respiratory symptoms and nasal 
virus load in the asthmatic group [r=0.79, p=0.01], but none in normal subjects (Figure 4). 
 
Relationship between immunopathology and clinical illness severity and virus load 
Lower airway inflammation was related to clinical illness severity in asthmatic subjects as both 
BAL neutrophils [r=-0.74, p=0.021] and eosinophils [r=-0.7, p=0.049] were significantly related 
to maximal fall in PEF  and sputum eosinophil counts on day 3 correlated with total lower 
respiratory symptoms [r=0.83, p=0.042] and on day 7 with fall in PC10 histamine [r=-0.87, 
p=0.05] , there were no such relationships in normal subjects (p=NS). 
 
Relationship between Th1/2 immune responses and clinical illness severity and virus load 
We investigated responses in the lower airway and their relation to lower respiratory outcomes 
and found that IFN-γ production by BAL CD4+ T cells was associated with protection, as 
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stronger responses were strongly related to less severe falls in PEF [(r=0.85, p = 0.004)] (Figure 
5A), while in contrast, BAL CD4+ T cell production of the Th2 cytokines IL-4, IL-5 and IL-13 
were all associated with adverse outcomes, as stronger responses were related to more severe 
lower respiratory symptom scores [(IL-4 r=0.7, p = 0.03; IL-5 r=0.75, p = 0.02; IL-13 r=0.68, p = 
0.045)] (Figure 5B). 
 
Conclusions 
 We have used experimental RV infection in asthmatic and normal volunteers to 
investigate the pathogenesis of virus induced asthma exacerbations. We found that asthmatic 
subjects had markedly increased lower respiratory symptoms compared with normal subjects 
who developed only minimal lower respiratory symptoms. The total lower respiratory tract 
symptom score in asthmatics was >6 times greater than that recorded by the normal volunteers. In 
addition, only asthmatic subjects had reductions in lung function and increases in bronchial 
hyperreactivity in response to infection. These observations confirm that RV infection in asthma 
is associated with greatly increased lower respiratory clinical illness severity. In conclusion, we 
have demonstrated clear differences between the responses of asthmatic and normal subjects to 
RV infection: in terms of clinical symptoms and airway physiology. We have related these 
changes to virus load and both clinical outcomes and virus load with airways inflammation. 
Further, we demonstrate that Th1 cytokines are associated with protection from exacerbation 
while Th2 cytokines were associated with increased disease severity. These observations provide 
compelling evidence supporting an important role for RV induced lower airway inflammation in 
precipitating asthma exacerbations, perhaps through impaired Th1and augmented Th2 responses. 
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Abstract and Aim 
 Viral infections are the most frequent cause of COPD exacerbations. The recent 
development of a human experimental model of rhinovirus-induced COPD exacerbations 
represents an innovative tool with the potential to increase our understanding of the inflammatory 
and immunological mechanisms that lead COPD patients to exacerbate after respiratory virus 
infections. Moreover this model will provide the opportunity to test, in a carefully controlled 
setting, novel pharmacological compounds with potential for treating and preventing COPD 
exacerbations. In this chapter we will discuss preliminary reports regarding the development of 
this human model of virus induced COPD exacerbation. 
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In vitro data document that respiratory virus infection can lead to COPD exacerbation via 
the production of several proinflammatory molecules that are relevant to the pathogenesis of 
COPD exacerbation (1-4). However, although in vitro models can provide important insights into 
the molecular mechanisms of inflammatory and immune responses to viral and bacterial 
infections, the in vitro data require validation using in vivo models.   
Bacterial infections have been considered important causes of COPD exacerbations for a 
long time. Nevertheless, while several mechanisms [e.g. induction of mucus hypersecretion (5), 
reduction of ciliary beat frequency (6) and enhancement of neutrophilic inflammation (7)] have 
been proposed to explain how bacterial infection can trigger COPD exacerbations, no animal 
model of bacteria induced COPD exacerbation is available.  Until recently this was also true for 
viral exacerbations. 
Carrying out studies of naturally occurring COPD exacerbations has proved difficult for a 
number of reasons including non reporting of exacerbations by patients, lack of baseline data 
before exacerbations, wide variation in aetiology, variation in timing of sampling relative to onset 
of exacerbation and finally carrying out invasive airway investigations in acutely unwell patients 
is difficult and may jeopardize their health.  One way to overcome these obstacles is the 
development of a human experimental model that would allow studies to take place under 
controlled conditions. The first step towards development of such a model has been recently 
realised (8) with the reporting of the first study evaluating the effects of an experimental 
rhinovirus infection in COPD patients.  
In this pilot study mild COPD patients were selected for experimental infection with the 
purpose a) of evaluating whether the procedure is safe in patients with mild COPD (mean FEV1 
was 74.8% predicted) and b) of providing preliminary data on whether experimental rhinovirus 
infection in COPD patients is per se sufficient to trigger an exacerbation. As safety was the prime 
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concern, a very carefully designed rhinovirus dose escalation study was performed in a small 
(n=5) group of subjects - to determine the minimum dose of virus able to induce clinical colds in 
80% (4 out of 5) of the inoculated subjects. Surprisingly, all of the first 4 patients exposed to the 
initial lowest dose of rhinovirus inoculum experienced not only cold symptoms but also lower 
respiratory tract symptoms characteristic of a COPD exacerbation associated with a significant 
fall in lung function (8) as occurs with naturally occurring exacerbations (9). The severity of the 
exacerbations induced was graded mild to moderate, thus achieving the primary aim of the study 
– to show that experimental rhinovirus infection could be safely carried out in mild COPD 
patients. 
This model also showed that experimental rhinovirus infection can cause exacerbation in 
COPD patients and that this model has the potential to provide a valid model of naturally 
occurring COPD exacerbation. In COPD this is so far the only scenario in which a specific 
aetiology has been experimentally proven to induce exacerbation.  
Two potentially important preliminary observations arose from this study: i) COPD 
patients developed colds and exacerbations with 100- to 1,000-fold lower doses of virus than 
used in previous studies in asthmatic and normal volunteers; ii) there was a 3 to 4 days gap 
between the peak of cold symptoms and the peak of lower respiratory symptoms (8) (figure 1). 
These data suggest that COPD patients may be highly susceptible to virus infection and that if an 
effective antiviral or anti-inflammatory treatment could be given at the onset of cold symptoms, 
this could possibly change the clinical outcome of the viral infection in COPD. These preliminary 
findings clearly require confirmation in a larger study of COPD patients. 
In a similar experimental model it has been recently documented in asthmatic patients that 
the severity of the virus-induced exacerbations, both in terms of symptoms, lung function 
reduction and inflammation in the airways, was inversely related to the production of a novel 
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class of interferons called IFN-λ (10). An impaired innate immune response can therefore be one 
of the mechanisms of increased susceptibility of asthmatic patients to respiratory viral infections. 
The new model in COPD will give the opportunity to test whether similar or different immune 
deficiencies are present in COPD, and if so, whether modulation and/or restoring of the immune 
response could represent a plausible pharmacological approach to treat/prevent COPD 
exacerbations. 
To further validate the results achieved in the in vivo experimental model in COPD and to 
investigate more deeply the mechanisms of viral induced COPD exacerbations, a larger study has 
been recently undertaken and preliminary findings published in form of an abstract (11). In this 
study 21 subjects (10 mild COPD patients and 11 age- and smoking-matched controls) have been 
enrolled. The results confirm that the model is feasible and safe. Symptomatic colds were 
accompanied by lower respiratory tract symptoms in both groups with breathlessness increasing 
significantly only in the COPD group. Interestingly, at variance with smokers with normal lung 
function, sputum neutrophils significantly increased in COPD patients following experimental 
infection. These data indicate that experimental RV infection in COPD induces symptoms, lung 
function changes and systemic and airway inflammation similar to that observed in naturally-
occurring exacerbations supporting, for the first time, a causal relationship between rhinovirus 
infection and COPD exacerbations. The development of such an experimental model in which 
causation is clearly defined and in which detailed clinical studies on mechanisms of disease can 
be carried out, will offer an invaluable tool to increase our understanding of the specific 
immunological and inflammatory events that lead COPD patients to exacerbate after viral 
infection.  Moreover this model will offer the possibility to highlight and to test novel 
pharmacological targets able to treat and/or prevent viral induced COPD exacerbations.  
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Figure 1 
 
 
 
 
 
 
 
 
Figure 1 legend 
 
Upper (URT) and lower (LRT) respiratory tract symptoms of rhinovirus in vivo experimentally 
infected COPD patients. A 3 to 4 days gap between the peak of cold symptoms and the peak of 
lower respiratory symptoms was documented (8). This data suggests that if an effective antiviral 
or anti-inflammatory treatment could be given at the onset of cold 
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